WO2022129629A1 - Lipocalin mutein dry powder formulation for treatment of asthma - Google Patents
Lipocalin mutein dry powder formulation for treatment of asthma Download PDFInfo
- Publication number
- WO2022129629A1 WO2022129629A1 PCT/EP2021/086730 EP2021086730W WO2022129629A1 WO 2022129629 A1 WO2022129629 A1 WO 2022129629A1 EP 2021086730 W EP2021086730 W EP 2021086730W WO 2022129629 A1 WO2022129629 A1 WO 2022129629A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dry powder
- fragment
- variant
- lipocalin mutein
- subject
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 465
- 238000009472 formulation Methods 0.000 title claims abstract description 430
- 239000000843 powder Substances 0.000 title claims abstract description 311
- 102000019298 Lipocalin Human genes 0.000 title claims abstract description 310
- 108050006654 Lipocalin Proteins 0.000 title claims abstract description 310
- 238000011282 treatment Methods 0.000 title claims abstract description 107
- 208000006673 asthma Diseases 0.000 title claims abstract description 61
- 239000012634 fragment Substances 0.000 claims abstract description 263
- 241000282414 Homo sapiens Species 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims description 114
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 84
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 84
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 84
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 79
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 76
- DNDWZFHLZVYOGF-KKUMJFAQSA-N Leu-Leu-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O DNDWZFHLZVYOGF-KKUMJFAQSA-N 0.000 claims description 66
- 108010049589 leucyl-leucyl-leucine Proteins 0.000 claims description 66
- 239000011859 microparticle Substances 0.000 claims description 41
- 150000001413 amino acids Chemical group 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 238000011321 prophylaxis Methods 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 description 116
- 229940112141 dry powder inhaler Drugs 0.000 description 91
- 229940074410 trehalose Drugs 0.000 description 78
- 239000007921 spray Substances 0.000 description 69
- 238000012360 testing method Methods 0.000 description 65
- 125000003275 alpha amino acid group Chemical group 0.000 description 50
- 239000002775 capsule Substances 0.000 description 49
- 239000002245 particle Substances 0.000 description 35
- 102000005962 receptors Human genes 0.000 description 35
- 108020003175 receptors Proteins 0.000 description 35
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 239000006172 buffering agent Substances 0.000 description 33
- 239000006199 nebulizer Substances 0.000 description 30
- 239000000243 solution Substances 0.000 description 30
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 27
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 27
- 235000001014 amino acid Nutrition 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 26
- 229940024606 amino acid Drugs 0.000 description 24
- 239000011521 glass Substances 0.000 description 24
- 239000000047 product Substances 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 21
- 239000007789 gas Substances 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 108090000765 processed proteins & peptides Proteins 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 101000946124 Homo sapiens Lipocalin-1 Proteins 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 238000001035 drying Methods 0.000 description 17
- 238000005259 measurement Methods 0.000 description 17
- 239000008363 phosphate buffer Substances 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 17
- 239000012929 tonicity agent Substances 0.000 description 17
- 230000027455 binding Effects 0.000 description 16
- 101000777204 Homo sapiens Putative ubiquitin carboxyl-terminal hydrolase 41 Proteins 0.000 description 15
- 102100031285 Putative ubiquitin carboxyl-terminal hydrolase 41 Human genes 0.000 description 15
- 239000012527 feed solution Substances 0.000 description 15
- 239000012669 liquid formulation Substances 0.000 description 15
- 239000011550 stock solution Substances 0.000 description 15
- 230000009885 systemic effect Effects 0.000 description 15
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 14
- 229910052782 aluminium Inorganic materials 0.000 description 14
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 14
- 229910000397 disodium phosphate Inorganic materials 0.000 description 14
- 235000019800 disodium phosphate Nutrition 0.000 description 14
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 14
- 235000019796 monopotassium phosphate Nutrition 0.000 description 14
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 14
- 239000001488 sodium phosphate Substances 0.000 description 14
- 239000008186 active pharmaceutical agent Substances 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 239000000523 sample Substances 0.000 description 13
- 102000010787 Interleukin-4 Receptors Human genes 0.000 description 12
- 108010038486 Interleukin-4 Receptors Proteins 0.000 description 12
- 239000013543 active substance Substances 0.000 description 12
- 239000000902 placebo Substances 0.000 description 12
- 229940068196 placebo Drugs 0.000 description 12
- 239000011148 porous material Substances 0.000 description 12
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 11
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 11
- 102000003752 Lipocalin 1 Human genes 0.000 description 11
- 108010057281 Lipocalin 1 Proteins 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
- 238000012512 characterization method Methods 0.000 description 10
- 229940125369 inhaled corticosteroids Drugs 0.000 description 10
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 9
- 229940088679 drug related substance Drugs 0.000 description 9
- 229940126602 investigational medicinal product Drugs 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- 238000012384 transportation and delivery Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 229940125389 long-acting beta agonist Drugs 0.000 description 8
- 238000012545 processing Methods 0.000 description 8
- 239000013074 reference sample Substances 0.000 description 8
- 239000003381 stabilizer Substances 0.000 description 8
- 102000004388 Interleukin-4 Human genes 0.000 description 7
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 239000000337 buffer salt Substances 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 description 6
- 125000000539 amino acid group Chemical group 0.000 description 6
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229940074409 trehalose dihydrate Drugs 0.000 description 6
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 5
- -1 biliverdins Substances 0.000 description 5
- 238000012552 review Methods 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 102000003816 Interleukin-13 Human genes 0.000 description 4
- 108090000176 Interleukin-13 Proteins 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 229940126534 drug product Drugs 0.000 description 4
- 239000007902 hard capsule Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 229940110339 Long-acting muscarinic antagonist Drugs 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000001174 ascending effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 102000054663 human IL4R Human genes 0.000 description 3
- 229940028885 interleukin-4 Drugs 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000000884 Airway Obstruction Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940124630 bronchodilator Drugs 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003595 mist Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 239000003016 pheromone Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 206010000364 Accessory muscle Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000036065 Airway Remodeling Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000835023 Homo sapiens Transcription factor A, mitochondrial Proteins 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000012347 Interleukin-4 Receptor alpha Subunit Human genes 0.000 description 1
- 108010061858 Interleukin-4 Receptor alpha Subunit Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010068956 Respiratory tract inflammation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102100026155 Transcription factor A, mitochondrial Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229950000321 benralizumab Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000029771 childhood onset asthma Diseases 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 210000001257 corticotroph Anatomy 0.000 description 1
- 230000003131 corticotrophic effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229950003468 dupilumab Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical group 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 229940127212 long-acting beta 2 agonist Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960005108 mepolizumab Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960000470 omalizumab Drugs 0.000 description 1
- 229940124624 oral corticosteroid Drugs 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 229960003254 reslizumab Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000012358 sourcing Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Definitions
- the present invention relates to the treatment of asthma in a human subject by administering by oral inhalation a dry powder formulation comprising a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein, or a variant or fragment thereof, to said subject.
- a dry powder formulation comprising a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein, or a variant or fragment thereof, to said subject.
- the invention also relates to the dry powder formulation comprising the anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein, or a variant or fragment thereof.
- Asthma is a chronic, complex and heterogeneous respiratory disease characterised by a range of pathogenic features including pulmonary inflammation, mucus hypersecretion, variable airway obstruction and airway remodelling. It is defined by a history of respiratory symptoms that include wheezing, shortness of breath and cough which vary over time and in severity. Both symptoms and airway obstruction can be triggered by a range of factors including exercise, exposure to inhaled irritants or allergens or respiratory infections. Patients are at risk of worsening of their asthma (exacerbations). These exacerbations of asthma can be life threatening and can significantly impact the patient’s quality of life. The treatment for most asthma patients, consists of a treatment regime of a controller and bronchodilator therapy.
- Inhaled corticosteroids are considered the “gold standard” in controlling asthma symptoms and long acting beta-agonists (LABA) are the most effective bronchodilators currently available.
- Oral corticosteroids remain standard of care in severe asthma but are associated with significant side-effects, whilst omalizumab, an anti-lgE monoclonal antibody; benralizumab, mepolizumab and reslizumab, anti-IL-5 antibodies, and dupilumab (US) a monoclonal antibody blocker of IL-4Ra and IL-13 offer a limited number of options for the severe patients. Additionally, patients frequently remain uncontrolled on ICS/LABA and even the limited number of alternative therapies, highlighting an important unmet need (Ray, A., et al., 2016, Current concepts of severe asthma. J. Clin. Invest. 126, 2394-2403).
- Interleukin-4, interleukin-13, interleukin-4-receptor alpha and the signal transducer and activator of transcription factor-6 are key components in the development of airway inflammation, mucus production, and airway hyper-responsiveness in asthma.
- Lipocalins are proteinaceous binding molecules, which have naturally evolved to bind ligands. Lipocalins occur in many organisms, including vertebrates, insects, plants and bacteria. The members of the lipocalin protein family (Pervaiz, S., & Brew, K. (1987) FASEB J. 1 , 209-214) are typically small, secreted proteins and have a single polypeptide chain.
- lipocalins have also been implicated in the regulation of the immune response and the mediation of cell homoeostasis (reviewed, for example, in Flower, D.R. (1996) Biochem. J. 318, 1-14 and Flower, D.R. et al. (2000) Biochim. Biophys. Acta 1482, 9-24).
- the lipocalins share unusually low levels of overall sequence conservation, often with sequence identities of less than 20%. In strong contrast, their overall folding pattern is highly conserved.
- the central part of the lipocalin structure consists of a single eight-stranded anti-parallel p - sheet closed back on itself to form a continuously hydrogen-bonded p-barrel. This p-barrel forms a central cavity.
- One end of the barrel is sterically blocked by the N-terminal peptide segment that runs across its bottom as well as three peptide loops connecting the p-strands.
- the other end of the p-barrel is open to solvent and encompasses a target-binding site, which is formed by four flexible peptide loops.
- TLPC Human tear lipocalin
- Tic also termed lipocalin-1, tear pre-albumin or von Ebner gland protein
- lipocalin-1 tear pre-albumin or von Ebner gland protein
- Tear lipocalin is an unusual lipocalin member in that it exhibits an unusually broad ligand specificity, when compared to other lipocalins, and in its high promiscuity for relative insoluble lipids (see Redl, B. (2000) Biochim. Biophys. Acta 1482; 241-248). This feature of tear lipocalin has been attributed to the protein's function in inhibiting bacterial and fungal growth at the cornea. A remarkable number of lipophilic compounds of different chemical classes such as fatty acids, fatty alcohols, phospholipids, glycolipids and cholesterol are endogenous ligands of this protein.
- tear lipocalin binds most strongly to the least soluble lipids (Glasgow, B.J. et al. (1995) Curr. Eye Res. 14, 363-372; Gasymov, O.K. et al. (1999) Biochim. Biophys. Acta 1433, 307-320).
- the 1.8-A crystal structure of tear lipocalin revealed an unusually large cavity inside its p-barrel (Breustedt, D.A. et al. (2005) J. Biol. Chem. 280, 1, 484-493).
- the resulting muteins have binding affinities for the selected ligand (KD) in the nanomolar range, in most cases >100 nM.
- International patent application WO 2008/015239 discloses muteins of tear lipocalin binding a given non-natural ligand, including the IL-4 receptor alpha. Binding affinities are in the nanomolar range.
- International patent application WO 2011/154420 describes high affinity muteins of human tear lipocalin that bind to human IL-4 receptor alpha in the nanomolar range and methods for producing such high affinity muteins.
- International patent application WO 2013/087660 describes the use of muteins of human tear lipocalin to treat disorders in which the IL-4/IL-13 pathway contributes to disease pathogenesis, including asthma.
- the advantages of pulmonary delivery of active agents include the convenience of patient self-administration, the potential for reduced drug side-effects, ease of delivery by inhalation, the elimination of needles, and the like.
- active agents such as lipocalin muteins
- Many clinical studies with inhaled proteins, peptides, DNA and small molecules have demonstrated that efficacy can be achieved both within the lungs and systemically.
- many molecules which require high payload for delivery, and in particular biological molecules present problems for the development of inhalable formulations.
- Formulations must provide stability to the biological payload, e.g. the lipocalin mutein, and have scalable manufacturability while also maintaining desirable physical characteristics to facilitate delivery into the lungs of a patient.
- the present invention is based on pre-formulation studies, a phase I crossover clinical study in humans to assess the pharmacokinetics (PK effects) of an inhaled anti-IL-4 receptor alpha (IL- 4Ra) human tear lipocalin, AZD1402, in healthy subjects and a two-part phase Ila study to assess efficacy and safety of AZD1402 administered to human patients with asthma as a dry powder.
- PK effects pharmacokinetics
- IL- 4Ra inhaled anti-IL-4 receptor alpha
- AZD1402 inhaled anti-IL-4 receptor alpha
- the amino acid sequence of AZD1402 is shown in Table 70 as SEQ ID NO:1.
- AZD1402 antagonises the IL-4 receptor alpha (IL-4Ra) and is designed for inhalation.
- the present invention provides a method for treating asthma in a human subject, wherein the method comprises administering by inhalation a dry powder formulation comprising a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO: 1, or a variant or fragment thereof, to said subject, wherein a nominal delivered dose of about 0.1 mg to about 30 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject by oral inhalation.
- IL-4Ra anti-IL-4 receptor alpha
- the invention also provides a dry powder formulation comprising a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein, or a variant or fragment thereof, for use in a method for treatment of asthma in a human subject, wherein the method comprises administering the dry powder formulation by inhalation, wherein a nominal delivered dose of about 0.1 mg to about 30 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject by oral inhalation, and wherein the anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprises the amino acid sequence set forth in SEQ ID NO: 1 , or a variant or fragment thereof.
- IL-4Ra anti-IL-4 receptor alpha
- the invention provides the use of a dry powder formulation comprising a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein, or a variant or fragment thereof, for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of asthma in a human subject, wherein the treatment comprises administering the dry powder formulation by inhalation, wherein a nominal delivered dose of about 0.1 mg to about 30 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject by oral inhalation, and wherein the anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprises the amino acid sequence set forth in SEQ ID NO: 1 , or a variant or fragment thereof.
- IL-4Ra anti-IL-4 receptor alpha
- a nominal delivered dose of about 0.5 mg, about 1mg, about 3mg, about 10mg or about 30mg of said lipocalin mutein, or variant or fragment thereof, may be administered to said subject by oral inhalation.
- a nominal delivered dose of about 0.5 mg, about 1mg, about 2mg, about 3mg, about 4mg, about 5mg, about 6mg, about 10mg or about 30mg of said lipocalin mutein, or variant or fragment thereof may be administered to said subject by oral inhalation.
- a nominal delivered dose of about 0.5mg of said lipocalin mutein, or variant or fragment thereof may be administered to said subject by oral inhalation.
- a nominal delivered dose of about 1mg of said lipocalin mutein, or variant or fragment thereof may be administered to said subject by oral inhalation.
- a nominal delivered dose of about 2mg of said lipocalin mutein, or variant or fragment thereof may be administered to said subject by oral inhalation. In some embodiments, a nominal delivered dose of about 3mg of said lipocalin mutein, or variant or fragment thereof, may be administered to said subject by oral inhalation. In some embodiments, a nominal delivered dose of about 4mg of said lipocalin mutein, or variant or fragment thereof, may be administered to said subject by oral inhalation. In some embodiments, a nominal delivered dose of about 5mg of said lipocalin mutein, or variant or fragment thereof, may be administered to said subject by oral inhalation.
- a nominal delivered dose of about 6mg of said lipocalin mutein, or variant or fragment thereof may be administered to said subject by oral inhalation. In some embodiments, a nominal delivered dose of about 10mg of said lipocalin mutein, or variant or fragment thereof, may be administered to said subject by oral inhalation. In some embodiments, a nominal delivered dose of about 30mg of said lipocalin mutein, or variant or fragment thereof, may be administered to said subject by oral inhalation.
- the invention also provides a method for treating asthma in a human subject, wherein the method comprises administering by inhalation a dry powder formulation comprising a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO: 1 , or a variant or fragment thereof, to said subject, wherein a nominal metered dose of about 0.2mg to about 40 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject by oral inhalation.
- IL-4Ra anti-IL-4 receptor alpha
- the invention also provides a dry powder formulation comprising a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein, or a variant or fragment thereof, for use in a method for treatment of asthma in a human subject, wherein the method comprises administering the dry powder formulation by inhalation, wherein a nominal metered dose of about 0.2mg to about 40 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject by oral inhalation, and wherein the anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprises the amino acid sequence set forth in SEQ ID NO: 1, or a variant or fragment thereof.
- IL-4Ra anti-IL-4 receptor alpha
- the invention provides the use of a dry powder formulation comprising a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein, or a variant or fragment thereof, for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of asthma in a human subject, wherein the treatment comprises administering the dry powder formulation by inhalation, wherein a nominal metered dose of about 0.2mg to about 40 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject by oral inhalation, and wherein the anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprises the amino acid sequence set forth in SEQ ID NO: 1 , or a variant or fragment thereof.
- IL-4Ra anti-IL-4 receptor alpha
- a nominal metered dose of about 0.55mg, about 0.6mg, about 1.1 mg, about 3.3mg, about 11.1mg, about 12mg or about 36mg of said lipocalin mutein, or variant or fragment thereof, may be administered to said subject.
- a nominal metered dose of about 0.55mg, about 0.6mg, about 1.1mg, about 2.2mg, about 3.3mg, about 4.4mg, about 5.5mg, about 6.6 mg, about 11.1 mg, about 12mg or about 36mg of said lipocalin mutein, or variant or fragment thereof, may be administered to said subject.
- a nominal metered dose of about 0.55mg of said lipocalin mutein, or variant or fragment thereof may be administered to said subject. In some embodiments, a nominal metered dose of about 0.6mg of said lipocalin mutein, or variant or fragment thereof, may be administered to said subject. In some embodiments, a nominal metered dose of about 1.1mg of said lipocalin mutein, or variant or fragment thereof, may be administered to said subject. In some embodiments, a nominal metered dose of about 2.2mg of said lipocalin mutein, or variant or fragment thereof, may be administered to said subject.
- a nominal metered dose of about 3.3mg of said lipocalin mutein, or variant or fragment thereof may be administered to said subject. In some embodiments, a nominal metered dose of about 4.4mg of said lipocalin mutein, or variant or fragment thereof, may be administered to said subject. In some embodiments, a nominal metered dose of about 5.5mg of said lipocalin mutein, or variant or fragment thereof, may be administered to said subject. In some embodiments, a nominal metered dose of about 6.6mg of said lipocalin mutein, or variant or fragment thereof, may be administered to said subject.
- a nominal metered dose of about 11.1mg of said lipocalin mutein, or variant or fragment thereof may be administered to said subject. In some embodiments, a nominal metered dose of about 12mg of said lipocalin mutein, or variant or fragment thereof, may be administered to said subject. In some embodiments, a nominal metered dose of about 36mg of said lipocalin mutein, or variant or fragment thereof, may be administered to said subject. In any of the aspects or embodiments of the invention described above, the lipocalin mutein, or variant or fragment thereof, may administered to said subject at least once per day. In some embodiments, the lipocalin mutein, or variant or fragment thereof, is administered to said subject once per day. In some embodiments, the lipocalin mutein, or variant or fragment thereof, is administered to said subject twice daily.
- the nominal delivered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject once per day is about 2.5mg, about 5mg, about 10mg, about 15mg, about 20mg or about 25 mg.
- the nominal delivered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject once per day is about 2.5mg. In some embodiments, the nominal delivered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject once per day is about 5mg. In some embodiments, the nominal delivered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject once per day is about 10mg. In some embodiments, the nominal delivered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject once per day is about 15mg.
- the nominal delivered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject once per day is about 20mg. In some embodiments, the nominal delivered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject once per day is about 25mg.
- the nominal delivered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 0.5mg, about 1mg, about 3mg, about 10mg or about 30mg.
- the nominal delivered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 0.5mg, about 1 mg, about 2mg, about 3mg, about 4mg, about 5mg, about 6mg, about 10mg or about 30mg.
- the nominal delivered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 0.5mg. In some embodiments, the nominal delivered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 1mg. In some embodiments, the nominal delivered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 2mg. In some embodiments, the nominal delivered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 3mg.
- the nominal delivered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 4mg. In some embodiments, the nominal delivered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 5mg. In some embodiments, the nominal delivered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 6mg. In some embodiments, the nominal delivered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 10mg. In some embodiments, the nominal delivered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 30mg.
- a total nominal delivered dose of about 1 mg, about 2mg, about 6mg, about 20mg or about 60mg of said lipocalin mutein, or variant or fragment thereof is administered to said subject per day, e.g. with one, two or more doses being administered to the subject per day, such that the total nominal delivered dose per day is about 1 mg, about 2mg, about 6mg, about 20mg or about 60mg.
- a total nominal delivered dose of about 1 mg, about 2mg, about 4mg, about 6mg, about 8mg, about 10mg, about 12mg, about 20mg or about 60mg of said lipocalin mutein, or variant or fragment thereof is administered to said subject per day, e.g. with one, two or more doses being administered to the subject per day, such that the total nominal delivered dose per day is about 1 mg, about 2mg, about 4mg, about 6mg, about 8mg, about 10mg, about 12mg, about 20mg or about 60mg.
- a total nominal delivered dose of about 2.5mg, about 5mg, about 10mg, about 15mg, about 20mg or about 25mg of said lipocalin mutein, or variant or fragment thereof is administered to said subject per day, e.g. with one, two or more doses being administered to the subject per day, such that the total nominal delivered dose per day is about 2.5mg, about 5mg, about 10mg, about 15mg, about 20mg or about 25mg.
- a total nominal delivered dose of about 1 mg of said lipocalin mutein, or variant or fragment thereof is administered to said subject per day. In some embodiments, a total nominal delivered dose of about 2 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject per day. In some embodiments, a total nominal delivered dose of about 2.5 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject per day. In some embodiments, a total nominal delivered dose of about 4 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject per day.
- a total nominal delivered dose of about 5 mg of said lipocalin mutein, or variant or fragment thereof is administered to said subject per day. In some embodiments, a total nominal delivered dose of about 6 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject per day. In some embodiments, a total nominal delivered dose of about 8 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject per day. In some embodiments, a total nominal delivered dose of about 10 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject per day.
- a total nominal delivered dose of about 12 mg of said lipocalin mutein, or variant or fragment thereof is administered to said subject per day. In some embodiments, a total nominal delivered dose of about 15 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject per day. In some embodiments, a total nominal delivered dose of about 20 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject per day. In some embodiments, a total nominal delivered dose of about 25 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject per day. In some embodiments, a total nominal delivered dose of about 60 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject per day.
- the nominal metered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 0.55mg, about 0.6mg, about 1.1 mg, about 3.3mg, about 11.1 mg, about 12mg or about 36mg.
- the nominal metered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 0.55mg, about 0.6mg, about 1.1 mg, about 2.2mg, about 3.3mg, about 4.4mg, about 5.5mg, about 6.6mg, about 11.1 mg, about 12mg or about 36mg.
- the nominal metered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 0.55mg. In some embodiments, the nominal metered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 0.6mg. In some embodiments, the nominal metered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 1.1mg. In some embodiments, the nominal metered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 2.2mg.
- the nominal metered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 3.3mg. In some embodiments, the nominal metered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 4.4mg. In some embodiments, the nominal metered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 5.5mg. In some embodiments, the nominal metered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 6.6mg.
- the nominal metered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 11.1 mg. In some embodiments, the nominal metered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 12mg. In some embodiments, the nominal metered dose for each dose of said lipocalin mutein, or variant or fragment thereof, administered to said subject twice per day is about 36mg.
- a total nominal metered dose of about 1.1 mg, about 1.2mg, about 2.2mg, about 6.6mg, about 22.2mg, about 24mg or about 72mg of said lipocalin mutein, or variant or fragment thereof is administered to said subject per day, e.g. with one, two or more doses being administered to the subject per day, such that the total nominal metered dose per day is about 1.1 mg, about 1.2mg, about 2.2mg, about 6.6mg, about 22.2mg, about 24mg or about 72mg.
- a total nominal metered dose of about 1.1 mg, about 1.2mg, about 2.2mg, about 4.4mg, about 6.6mg, about 8.8mg, about 11 mg, about 13.2mg, about 22.2mg, about 24mg or about 72mg of said lipocalin mutein, or variant or fragment thereof is administered to said subject per day, e.g. with one, two or more doses being administered to the subject per day, such that the total nominal metered dose per day is about 1.1 mg, about 1.2mg, about 2.2mg, about 4.4mg, about 6.6mg, about 8.8mg, about 11 mg, about 13.2mg, about 22.2mg, about 24mg or about 72mg.
- a total nominal metered dose of about 1.1 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject per day. In some embodiments, a total nominal metered dose of about 1.2 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject per day. In some embodiments, a total nominal metered dose of about 2.2 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject per day. In some embodiments, a total nominal metered dose of about 4.4 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject per day.
- a total nominal metered dose of about 6.6 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject per day. In some embodiments, a total nominal metered dose of about 8.8 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject per day. In some embodiments, a total nominal metered dose of about 11 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject per day. In some embodiments, a total nominal metered dose of about 13.2 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject per day.
- a total nominal metered dose of about 22.2 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject per day. In some embodiments, a total nominal metered dose of about 24 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject per day. In some embodiments, a total nominal metered dose of about 72 mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject per day.
- the formulation may include a plurality of microparticles, the microparticles comprising said lipocalin mutein, or variant or fragment thereof.
- the dry powder formulation comprises trehalose, leucine and/or trileucine, either singly or in any combination thereof.
- the dry powder formulation may comprise (i) trehalose, (ii) trehalose and leucine, (iii) trehalose, leucine and trileucine, or (iv) trehalose and trileucine.
- the dry powder formulation further comprises a buffering agent, such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous disodium phosphate as a buffering agent, and a tonicity agent, such as sodium chloride.
- a buffering agent such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous disodium phosphate as a buffering agent
- a tonicity agent such as sodium chloride.
- the invention provides a dry powder formulation, wherein said formulation comprises an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO: 1 , or a variant or fragment thereof.
- IL-4Ra anti-IL-4 receptor alpha
- the dry powder formulation comprises trehalose, leucine and/or trileucine, either singly or in any combination thereof.
- the dry powder formulation may comprise (i) trehalose, (ii) trehalose and leucine, (iii) trehalose, leucine and trileucine, or (iv) trehalose and trileucine.
- the dry powder formulation comprises trehalose, leucine and trileucine.
- the dry powder formulation further comprises a buffering agent, such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous disodium phosphate as a buffering agent, and a tonicity agent, such as sodium chloride.
- a buffering agent such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous disodium phosphate as a buffering agent
- a tonicity agent such as sodium chloride.
- the dry powder formulation further comprises a buffering agent, such as a histidine buffer, and a tonicity agent, such as sodium chloride.
- the dry powder formulation provides a nominal delivered dose of about 0.1 mg to about 30 mg of said lipocalin mutein, or variant or fragment thereof, when said formulation is administered to said subject by oral inhalation.
- the dry powder formulation provides a nominal delivered dose about 0.5 mg, about 1mg, about 3mg, about 10mg or about 30mg of said lipocalin mutein, or variant or fragment thereof, when said formulation is administered to said subject by oral inhalation.
- the dry powder formulation provides a nominal delivered dose about 0.5 mg, about 1mg, about 2mg, about 3mg, about 4mg, about 5mg, about 6mg, about 10mg or about 30mg of said lipocalin mutein, or variant or fragment thereof, when said formulation is administered to said subject by oral inhalation.
- the dry powder formulation provides a nominal delivered dose about 2.5 mg, about 5mg, about 10mg, about 15mg, about 20mg or about 25mg of said lipocalin mutein, or variant or fragment thereof, when said formulation is administered to said subject by oral inhalation.
- the nominal delivered dose is about 0.5mg. In some embodiments, the nominal delivered dose is about 1mg. In some embodiments, the nominal delivered dose is about 2mg. In some embodiments, the nominal delivered dose is about 2.5mg. In some embodiments, the nominal delivered dose is about 3mg. In some embodiments, the nominal delivered dose is about 4mg. In some embodiments, the nominal delivered dose is about 5mg. In some embodiments, the nominal delivered dose is about 6mg. In some embodiments, the nominal delivered dose is about 10mg. In some embodiments, the nominal delivered dose is about 15mg. In some embodiments, the nominal delivered dose is about 20mg. In some embodiments, the nominal delivered dose is about 25mg. In some embodiments, the nominal delivered dose is about 30mg.
- the dry powder formulation comprises a nominal metered dose of about 0.2mg to about 40 mg of said lipocalin mutein, or variant or fragment thereof, for administration to said subject by oral inhalation. In some embodiments, the dry powder formulation provides a nominal metered dose of about 0.55mg, about 0.6mg, about 1.1 mg, about 3.3mg, about 11.1mg, about 12mg or about 36mg of said lipocalin mutein, or variant or fragment thereof, for administration to said subject by oral inhalation.
- the dry powder formulation provides a nominal metered dose of about 0.55mg, about 0.6mg, about 1.1 mg, about 2.2mg, about 3.3mg, about 4.4mg, about 5.5mg, about 6.6mg, about 11.1mg, about 12mg or about 36mg of said lipocalin mutein, or variant or fragment thereof, for administration to said subject by oral inhalation.
- the nominal metered dose is about 0.55mg. In some embodiments, the nominal metered dose is about 0.6mg. In some embodiments, the nominal metered dose is about 1.1 mg. In some embodiments, the nominal metered dose is about 2.2mg. In some embodiments, the nominal metered dose is about 3.3mg. In some embodiments, the nominal metered dose is about 4.4mg. In some embodiments, the nominal metered dose is about 5.5mg. In some embodiments, the nominal metered dose is about 6.6mg. In some embodiments, the nominal metered dose is about 11.1 mg. In some embodiments, the nominal metered dose is about 12mg. In some embodiments, the nominal metered dose is about 36mg.
- the dry powder formulation may include a plurality of microparticles, the microparticles comprising said lipocalin mutein, or variant or fragment thereof.
- the invention also provides a method for treating asthma in a human subject, wherein the method comprises administering by oral inhalation the dry powder formulation described in any of the embodiments above to said subject.
- the invention also provides the dry powder formulation described in any of the embodiments above for use in a method for treatment of asthma in a human subject, wherein the method comprises administering the dry powder formulation to said subject by oral inhalation.
- the invention provides the use of the dry powder formulation described in any of the embodiments above for the manufacture of a medicament for the therapeutic and/or prophylactic treatment of asthma in a human subject, wherein the treatment comprises administering the dry powder formulation to said subject by oral inhalation.
- Figure 1 shows the study flow chart for the phase I clinical trial described in Example 16.
- Test product A 18 mg nominal delivered dose of AZD1402 nebulizer solution administered via the InnoSpire Go nebulizer.
- Test product B 10 mg nominal delivered dose of AZD1402 inhalation powder administered via the Plastiape Monodose inhaler.
- Test product C 30 mg nominal delivered dose of AZD1402 inhalation powder administered via the Plastiape Monodose inhaler.
- Figure 2 shows the Geometric Mean (*/SD) Serum Concentration (ng/ml_) of AZD1402 Versus Time Following Inhalation via InnoSpire Go Nebulizer (18 mg nominal delivered dose), Plastiape Monodose Inhaler (10 mg or 30 mg nominal delivered dose) (Pharmacokinetic Analysis Set-Linear Scale).
- A Nebulizer solution administered via InnoSpire Go nebulizer (18 mg nominal delivered dose);
- B Inhalation powder administered via Plastiape Monodose inhaler (10 mg nominal delivered dose);
- C Inhalation powder administered via Plastiape Monodose inhaler (30 mg nominal delivered dose).
- SD Standard Deviation.
- N number of subjects.
- GEOMETRIC MEAN / SD exp(mean[log ⁇ PK Cone ⁇ ] - std[log ⁇ PK Cone ⁇ ]).
- GEOMETRIC MEAN * SD exp(mean[log ⁇ PK Cone ⁇ ] + std[log ⁇ PK Cone) ⁇ ]).
- Vertical lines represent the geometric mean 7 SD.
- Figure 3 shows the Geometric Mean (7SD) Serum Concentration (ng/mL) of AZD1402 Versus Time Following Inhalation via InnoSpire Go Nebulizer (18 mg nominal delivered dose), Plastiape Monodose Inhaler (10 mg or 30 mg nominal delivered dose) (Pharmacokinetic Analysis Set - Semi-Logarithmic Scale).
- A Nebulizer solution administered via InnoSpire Go nebulizer (18 mg nominal delivered dose);
- B Inhalation powder administered via Plastiape Monodose inhaler (10 mg nominal delivered dose);
- C Inhalation powder administered via Plastiape Monodose inhaler (30 mg nominal delivered dose).
- SD Standard Deviation.
- N number of subjects.
- GEOMETRIC MEAN / SD exp(mean[log ⁇ PK Cone ⁇ ] - std[log ⁇ PK Cone ⁇ ]).
- GEOMETRIC MEAN * SD exp(mean[log ⁇ PK Cone ⁇ ] + std[log ⁇ PK Cone) ⁇ ]).
- Vertical lines represent the geometric mean 7 SD.
- Figure 4 shows AZD1402 steady-state serum concentrations after 12 days of once-a-day and twice-a-day dosing with 5 and 1 mg doses, respectively.
- the present invention relates to a method of treating asthma in a human subject.
- the asthma may, for example, be moderate or severe asthma.
- moderate asthma the patient can talk in phrases, has an increased respiratory rate, the accessary muscles are not used, the pulse rate is 100-120 bpm, the oxygen saturation (on air) is 90-95% and the peak expiratory flow (PEF) is >50% predicted or best (see Pocket Guide for Asthma Management and Prevention, Global Initiative for Asthma, Updated 2020).
- severe asthma the patient talks in words, has a respiratory rate of >30/min, the accessory muscles are in use, the pulse rate is >120bpm, the oxygen saturation (on air) is ⁇ 90%.
- the asthma is allergic asthma.
- the method of treating asthma comprises administering a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein, or a variant or fragment thereof, comprising the amino acid sequence set forth in SEQ ID NO: 1 .
- IL-4Ra anti-IL-4 receptor alpha
- terapéuticaally effective amount it is meant a dose that produces the effects for which it is administered.
- a “therapeutically effective amount” of a lipocalin mutein as described herein may vary according to factors such as age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art.
- a therapeutically effective amount, when used in the present application, is also one in which any toxic or detrimental effects of the lipocalin mutein are outweighed by the therapeutically beneficial effects.
- Interleukin-4 receptor alpha chain is a type I transmembrane protein that can bind interleukin 4 and interleukin 13 to regulate IgE antibody production in B cells.
- the encoded protein also can bind interleukin 4 to promote differentiation of Th2 cells.
- Lipocalin muteins that are specific for IL-4 receptor alpha (IL-4Ra), in particular human IL-4Ra are disclosed in International patent publications WO 2008/015239, WO 2011/154420, and WO 2013/087660.
- Human interleukin-4 receptor alpha chain may have the amino acid sequence of SWISS PROT Data Bank Accession No. P24394, which is shown as SEQ ID NO:4, or of fragments thereof.
- An illustrative example of a fragment of human interleukin-4 receptor alpha chain includes amino acids 26 to 232 of IL-4 receptor alpha.
- the IL-4Ra specific lipocalin mutein having the amino acid sequence shown as SEQ ID NO:1 is a mutein of human tear lipocalin.
- mutein refers to the exchange, deletion, or insertion of one or more nucleotides or amino acids, compared to the naturally occurring (wild-type) nucleic acid or protein “reference” scaffold, which is preferably mature human tear lipocalin shown as SEQ ID NO: 3.
- reference scaffold also includes mutein, or fragment or variant thereof, as described herein.
- the amino acid sequence of human tear lipocalin is provided by SWISS-PROT Data Bank Accession Number P31025, as shown in SEQ ID NO: 2. Mature human tear lipocalin does not include the N-terminal signal peptide that is included in the sequence of SWISS-PROT Accession Number P31025, i.e. it lacks the N-terminal signal peptide (amino acids 1-18) that is included in the sequence of SWISS-PROT Accession Number P31025. The amino acid sequence of mature human tear lipocalin is shown in SEQ ID NO:3.
- the lipocalin mutein used in the present invention comprises SEQ ID NO:1 or is a variant or fragment thereof.
- the lipocalin mutein shown as SEQ ID NO:1 is a variant of mature human tear lipocalin shown as SEQ ID NO:3, which lacks the first four amino acids and includes inter alia the following amino acid substitutions at the positions corresponding to the sequence positions of the amino acid sequence of mature human tear lipocalin shown as SEQ ID NO: 3: Arg 26 ⁇ Ser, Glu 27 Arg, Phe 28 ⁇ Cys, Glu 30 ⁇ Arg, Met 31 Ala, Asn 32 Vai, Leu 33 Tyr, Glu 34 Asn, Met 55 -» Ala, Leu 56 ⁇ Gin, lie 57 ⁇ • Arg, Ser 58 Lys, Cys 61 -> Trp, Glu 63 Lys, Asp 80 Ser, Lys 83 ⁇ Arg, Glu 104 ⁇ Leu, Leu 105 -> Cys, His 106 ⁇ Pro and Lys
- the lipocalin mutein used in the present invention comprises SEQ ID NO:1 or is a variant or fragment thereof.
- the lipocalin mutein shown as SEQ ID NO:1 is a variant of mature human tear lipocalin shown as SEQ ID NO:3, which lacks the first four amino acids and includes inter alia the following amino acid substitutions at the positions corresponding to the sequence positions of the amino acid sequence of mature human tear lipocalin shown as SEQ ID NO: 3: Arg 26 ⁇ Ser, Glu 27 Arg, Phe 28 ⁇ Cys, Glu 30 Arg, Met 31 Ala, Asn 32 ⁇ Vai, Leu 33 ⁇ Tyr, Glu 34 Asn, Vai 53 ⁇ Phe, Met 55 Ala, Leu 56 Gin, lie 57 ⁇ Arg, Ser 58 Lys, Cys 61--> Trp, Glu 63 Lys, Vai 64 ⁇ Tyr, Ala 66 ⁇ Leu, Asp 80 Ser, Lys 83 Arg, Tyr 100 ⁇ His,
- variant relates to derivatives of a protein or polypeptide that include mutations, for example by substitutions, deletions, insertions, and/or chemical modifications of an amino acid sequence or nucleotide sequence. In some embodiments, such mutations and/or chemical modifications do not reduce the functionality of the protein or peptide. Such substitutions may be conservative, i.e., an amino acid residue is replaced with a chemically similar amino acid residue.
- conservative substitutions are the replacements among the members of the following groups: 1) alanine, serine, and threonine; 2) aspartic acid and glutamic acid; 3) asparagine and glutamine; 4) arginine and lysine; 5) isoleucine, leucine, methionine, and valine; and 6) phenylalanine, tyrosine, and tryptophan.
- Such variants include proteins or polypeptides, wherein one or more amino acids have been substituted by their respective D-stereoisomers or by amino acids other than the naturally occurring 20 amino acids, such as, for example, ornithine, hydroxyproline, citrulline, homoserine, hydroxylysine, norvaline.
- variants also include, for instance, proteins or polypeptides in which one or more amino acid residues are added or deleted at the N- and/or C-terminus such as a deletion of four amino acids from the N-terminus and/or two amino acids from the C-terminus.
- a variant has at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 92%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity with the native sequence protein or polypeptide.
- a variant preferably retains the biological activity, e.g. binding the same target, of the protein or polypeptide from which it is derived.
- a variant of the lipocalin mutein comprising the amino acid set forth in SEQ ID NO:1 in accordance with the present invention has at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 92%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity with the amino acid sequence shown as SEQ ID NO:1 and retains the ability to bind to IL-4 receptor alpha, in particular human IL- 4Ra, or a fragment thereof.
- the variant of the lipocalin mutein is capable of inhibiting IL-4 from binding to IL-4Ra.
- a variant of the lipocalin mutein comprising the amino acid set forth in SEQ ID NO:1 in accordance with the present invention has at least about 50%, at least about 60%, at least about 65%, at least about 70%, at least about 72%, at least about 74%, at least about 75%, at least about 76%, at least about 77%, at least about 79%, at least about 80%, at least about 85%, at least about 90%, at least about 92%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity with the amino acid sequence of mature human tear lipocalin, shown as SEQ ID NO:3 and retains the ability to bind to IL-4 receptor alpha, in particular human IL-4Ra, or a fragment thereof.
- the variant of the lipocalin mutein is capable of inhibiting IL-4 from binding to IL-4Ra.
- sequence identity denotes a property of sequences that measures their similarity or relationship.
- sequence identity or “identity” as used in the present disclosure means the percentage of pair-wise identical residues - following (homologous) alignment of a sequence of a protein or polypeptide of the disclosure with a sequence in question - with respect to the number of residues in the longer of these two sequences. Sequence identity is measured by dividing the number of identical amino acid residues by the total number of residues and multiplying the product by 100.
- BLAST Altschul et al., Nucleic Acids Res, 1997)
- BLAST2 Altschul et al., J Mol Biol, 1990
- FASTA which uses the method of Pearson and Lipman (1988)
- TBLASTN program Altschul et al. (1990) supra
- GAP World Health Organization
- Smith-Waterman Smith and Waterman, J Mol Biol, 1981
- the percentage of sequence identity can, for example, be determined herein using the program BLASTP, version 2.2.5, November 16, 2002 (Altschul et al., Nucleic Acids Res, 1997).
- the percentage of homology is based on the alignment of the entire protein or polypeptide sequences (matrix: BLOSUM 62; gap costs: 11.1; cut off value set to 10 _ 3 ) including the polypeptide sequences, preferably using the wild-type protein scaffold as reference in a pairwise comparison. It is calculated as the percentage of numbers of “positives” (homologous amino acids) indicated as result in the BLASTP program output divided by the total number of amino acids selected by the program for the alignment. Sequence identity is commonly defined with reference to the algorithm GAP (Wisconsin GCG package, Accelerys Inc, San Diego USA).
- GAP uses the Needleman and Wunsch algorithm to align two complete sequences, maximising the number of matches and minimising the number of gaps, which are spaces in an alignment that are the result of additions or deletions of amino acids. Generally, default parameters are used, with a gap creation penalty equalling 12 and a gap extension penalty equalling 4.
- SEQ ID NO:1 can serve as “reference sequence”, while the amino acid sequence of a lipocalin different from the lipocalin mutein having the amino acid sequence shown as SEQ ID NO:1 described herein serves as “query sequence”.
- fragment as used herein in connection with the lipocalin muteins of the disclosure relates to proteins or peptides derived from the lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO:1 that are N-terminally and/or C-terminally truncated, i.e. lacking at least one of the N-terminal and/or C-terminal amino acids.
- Such a fragment may lack up to 1, up to 2, up to 3, up to 4, up to 5, up to 10, up to 15, up to 20, up to 25, or up to 30 (including all numbers in between) of the N-terminal and/or C-terminal amino acids.
- such a fragment may lack the one, two, three, or four N-terminal and/or one or two C-terminal amino acids.
- the fragment is preferably a functional fragment of a full-length lipocalin (mutein), which means that it preferably comprises the binding pocket of the full length lipocalin (mutein) from which it is derived.
- a functional fragment may comprise at least amino acids at positions 5-158, 1-156, 5-156, 5-153, 26-153, 5-150, 9-148, 12-140, 20-135, or 26-133 corresponding to the linear polypeptide sequence of mature human tear lipocalin.
- Such fragments may include at least 10, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90 or at least 100 consecutive amino acids of the sequence shown as SEQ ID NO: 1 and are usually detectable in an immunoassay of the lipocalin mutein having the amino acid sequence SEQ ID NO:1.
- a fragment may have at least about 50%, at least about 60%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 92%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% amino acid sequence identity with the amino acid sequence shown as SEQ ID NO:1.
- the fragment retains the ability to bind to IL-4 receptor alpha, in particular human IL- 4Ra, or to a fragment thereof.
- the fragment of the lipocalin mutein is capable of inhibiting IL-4 from binding to IL-4Ra.
- a “fragment” with respect to the corresponding target IL-4Ra of the disclosure refers to N-terminally and/or C-terminally truncated IL-4Ra or protein domains of IL-4Ro. Fragments of IL-4Ra as described herein retain the capability of the full- length IL-4Ra to be recognized and/or bound by a lipocalin mutein of the disclosure.
- the fragment may be an extracellular domain of IL-4Ra, such as an extracellular domain comprising amino acid residues 26-232 of UniProt P24394, which is shown as SEQ ID NO:5.
- a nominal delivered dose of about 0.1 mg to about 30 mg of the lipocalin mutein, or variant or fragment thereof is administered to the subject by oral inhalation of a dry powder formulation.
- a nominal delivered dose of about 0.5 mg, about 1mg, about 3mg, about 10mg or about 30mg of the lipocalin mutein, or variant or fragment thereof is administered to the subject by oral inhalation of a dry powder formulation.
- a nominal delivered dose of about 0.5 mg, about 1mg, about 2mg, about 3mg, about 4mg, about 5mg, about 6mg, about 10mg or about 30mg of the lipocalin mutein, or variant or fragment thereof, is administered to the subject by oral inhalation of a dry powder formulation.
- the nominal delivered dose is about 0.5mg.
- the nominal delivered dose is about 1mg.
- the nominal delivered dose is about 2mg.
- the nominal delivered dose is about 3mg.
- the nominal delivered dose is about 4mg.
- the nominal delivered dose is about 5mg.
- the nominal delivered dose is about 6mg. In some embodiments, the nominal delivered dose is about 10mg. In some embodiments, the nominal delivered dose is about 30mg.
- the nominal delivered dose is the target amount of lipocalin mutein, or variant or fragment thereof, the subject receives when inhaling the dry powder formulation. For example, it may be the amount of lipocalin mutein, or variant or fragment thereof, delivered from the mouthpiece of a device used to administer the dry powder formulation. Calculation of the nominal delivered dose is based on dry powder inhalation device efficiencies.
- the nominal metered dose is the target amount of lipocalin mutein, or variant or fragment thereof, present in the dry powder formulation for addition to an inhalation device.
- the nominal metered dose may be the target amount of lipocalin mutein, or variant or fragment thereof, filled in a capsule as a dry powder formulation, wherein the target amount is the average fill weight x the average active pharmaceutical ingredient (API) content.
- a nominal metered dose of about 0.2mg to about 40 mg of the lipocalin mutein, or variant or fragment thereof is administered to the subject by oral inhalation of a dry powder formulation.
- a nominal metered dose of about 0.65 mg, about 1.1mg, about 3.3mg, about 11.1mg, about 12mg or about 36mg of the lipocalin mutein, or variant or fragment thereof is administered to the subject by oral inhalation of a dry powder formulation.
- a nominal metered dose of about 0.55mg, about 0.6mg, about 1.1 mg, about 2.2mg, about 3.3mg, about 4.4mg, about 5.5mg, about 6.6mg, about 11.1mg, about 12mg or about 36mg of the lipocalin mutein, or variant or fragment thereof is administered to the subject by oral inhalation of a dry powder formulation.
- the lipocalin mutein may be administered to the human subject at least once per day and preferably twice per day, i.e. twice daily.
- a nominal delivered dose of about 0.5mg, about 1mg, about 3mg, about 10mg or about 30mg of the lipocalin mutein, or variant or fragment thereof is administered to the subject twice per day, i.e. twice daily
- each dose of about 0.5mg, about 1mg, about 3mg, about 10mg or about 30mg is administered to the subject twice per day, i.e. twice daily.
- the total nominal delivered dose of the lipocalin mutein, or variant or fragment thereof, administered to the subject per day is about 1mg, about 2mg, about 6mg, about 20mg or about 60mg.
- a nominal delivered dose of about 0.5mg, about 1mg, about 2mg, about 3mg, about 4mg, about 5mg, about 6mg, about 10mg or about 30mg of the lipocalin mutein, or variant or fragment thereof is administered to the subject twice per day, i.e.
- each dose of about 0.5mg, about 1mg, about 2mg, about 3mg, about 4mg, about 5mg, about 6mg, about 10mg or about 30mg is administered to the subject twice per day, i.e. twice daily.
- the total nominal delivered dose of the lipocalin mutein, or variant or fragment thereof, administered to the subject per day is about 1mg, about 2mg, about 4mg, about 6mg, about 8mg, about 10mg, about 12mg, about 20mg or about 60mg.
- each dose of about 0.65mg, about 1.1mg, about 3.3mg, about 11.1mg, about 12mg or about 36mg is administered to the subject twice per day, i.e. twice daily.
- each dose of about 0.65mg, about 1.1mg, about 3.3mg, about 11.1mg, about 12mg or about 36mg is administered to the subject twice per day, i.e. twice daily.
- the total nominal metered dose of the lipocalin mutein, or variant or fragment thereof, administered to the subject per day is about 1.1 mg, about 2.2mg, about 6.6mg, about 22.2mg, about 24mg or about 72mg.
- a nominal metered dose of about 0.55mg, about 0.6mg, about 1.1 mg, about 2.2mg, about 3.3mg, about 4.4mg, about 5.5mg, about 6.6mg, about 11.1 mg, about 12mg or about 36mg of the lipocalin mutein, or variant or fragment thereof is administered to the subject twice per day, i.e.
- each dose of about 0.55mg, about 0.6mg, about 1.1 mg, about 2.2mg, about 3.3mg, about 4.4mg, about 5.5mg, about 6.6mg, about 11.1 mg, about 12mg or about 36mg is administered to the subject twice per day, i.e. twice daily.
- the total nominal metered dose of the lipocalin mutein, or variant or fragment thereof, administered to the subject per day is about 1.1 mg, about 1.2mg, about 2.2mg, about 4.4mg, about 6.6mg, about 8.8mg, about 11 mg, about 13.2mg, about 22.2mg, about 24mg or about 72mg.
- a total nominal delivered dose of the lipocalin mutein, or variant or fragment thereof, of about 1mg, about 2mg, about 6mg, about 20mg or about 60mg is administered to the subject per day. In some embodiments, a total nominal delivered dose of the lipocalin mutein, or variant or fragment thereof, of about 1mg, about 2mg, about 4mg, about 6mg, about 8mg, about 10mg, about 12mg, about 20mg or about 60mg is administered to the subject per day.
- a total nominal metered dose of the lipocalin mutein, or variant or fragment thereof, of about 1.1 mg, about 2.2mg, about 6.6mg, about 22.2mg, about 24mg or about 72mg is administered to the subject per day.
- a total nominal metered dose of the lipocalin mutein, or variant or fragment thereof, of about 1.1 mg, about 1.2mg, about 2.2mg, about 4.4mg, about 6.6mg, about 8.8mg, about 11 mg, about 13.2mg, about 22.2mg, about 24mg or about 72mg is administered to the subject per day.
- a total nominal delivered dose or a total nominal metered dose may be achieved by any number of doses per day, e.g. 1, 2, 3, 4, or 5 doses per day.
- a total nominal delivered dose of the lipocalin mutein, or variant or fragment thereof, of about 1mg, about 2mg, about 6mg, about 20mg or about 60mg may be achieved by administering a nominal delivered dose of the lipocalin mutein, or variant or fragment thereof of about 1mg, about 2mg, about 6mg, about 20mg or about 60mg to the subject once per day.
- a total nominal metered dose of about 1.1 mg, about 1.2mg, about 2.2mg, about 6.6mg, about 22.2mg, about 24mg or about 72mg of the lipocalin mutein, or variant or fragment thereof may be achieved by administering a nominal metered dose of the lipocalin mutein, or variant or fragment thereof of about 1.1 mg, about 1.2mg, about 2.2mg, about 6.6mg, about 22.2mg, about 24mg or about 72mg to the subject once per day.
- a total nominal delivered dose of the lipocalin mutein, or variant or fragment thereof, of about 2.5mg, about 5mg, about 10mg, about 15mg, about 20mg or about 25mg may be achieved by administering a nominal delivered dose of the lipocalin mutein, or variant or fragment thereof of about 2.5mg, about 5mg, about 10mg, about 15mg, about 20mg or about 25mg to the subject once per day.
- the lipocalin mutein according to the present invention is administered to the human subject by inhalation of a dry powder formulation.
- the dry powder formulations are formulated for pulmonary delivery, including by inhalation via a dry powder inhaler (DPI).
- DPI dry powder inhaler
- Inhalation of a dry powder formulation is usually by oral inhalation.
- the dry powder formulation may, for example, be present in a capsule.
- Means and devices for inhaled administration of a dry powder formulation of the lipocalin mutein are known to the skilled person. Such means and devices include a single-dose dry powder inhaler, such as a capsule-based single-dose dry powder inhaler. Other means and devices suitable for directing inhaled administration of a dry powder formulation of a lipocalin mutein to the lung, such as a multi-dose dry powder inhaler, are also known in the art.
- a preferred capsule-based dry powder inhaler is rotating capsule inhaler, such as a Plastiape Monodose inhaler, e.g. the RPC Plastiape S.p.A RS01 Monodose Model 7, which is a Class I CE-marked medical device according to the Medical Device Directive 93/42/EEC.
- This inhaler delivers drug formulations to the lung in dry powder form and is intended for self-administration by the patient at home, outside the home and in institutions, such as hospitals and clinics.
- Lipocalin muteins for use in the present invention will usually be administered in the form of a dry powder formulation, which may comprise at least one component in addition to the lipocalin mutein.
- pharmaceutical compositions for use in accordance with the present invention may comprise, in addition to active ingredient, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient.
- the dry powder formulation may comprise a stabiliser, an aerosol performance enhancer, a buffering agent and a tonicity agent, as described in more detail below.
- dry powder formulation refers to a formulation that includes a plurality of solid microparticles in a powder composition that suitably contains less than about 20% moisture, more suitably less than 10% moisture, less than about 5-6% moisture, or less than about 3% moisture. As described herein, dry powder formulations can preferably be utilized for delivery via inhalation to a patient.
- a “microparticle” as used herein refers to a solid particle having a size mass mean diameter (MMD) of less than 20 pm.
- Mass mean diameter is a measure of the mean particle size of the microparticles, measured using a suitable method, including for example centrifugal sedimentation, electron microscopy, light scattering, laser diffraction.
- dry powder formulations described herein suitably contain a plurality of microparticles.
- plural refers to 2 or more of an item, and suitably refers to 5 or more, 10 or more, 50 or more, 100 or more, 500 or more, 1000 or more, etc.
- the dry powder formulations described herein further comprise a stabiliser to aid in stabilizing the formulation, and in particular, in stabilizing the active agent.
- a stabiliser refers to an excipient that stabilizes an active agent (suitably a polypeptide) in a dry powder formulation, suitably by substituting for water at the active agent surface during drying, or otherwise impeding the degradation process, and forms an amorphous solid that includes the active agent.
- Examples of stabilisers include amorphous saccharides, polymeric sugars, buffers, salts, or synthetic polymers (e.g., poly-L-glycolic acid), as well as mixtures of such components.
- the stabiliser is an amorphous saccharide.
- the stabilizer is the amorphous saccharide with high glass transition temperature, such as trehalose. The chemical structure of trehalose is provided below.
- trehalose is present at about 0.5% to about 99.5% (weight percentage, w/w %) of the dry powder formulation. In some embodiments, trehalose is present at about 5% to about 98% (w/w %) of the dry powder formulation. In preferred embodiments, trehalose is present at about 5% to about 95% (w/w %) of the dry powder formulation.
- the dry powder formulations of the invention preferably include an aerosol performance enhancer, such as trileucine and/or leucine.
- Trileucine refers to the chemical compound in which three leucine molecules are linked together in a peptide, as leucine-leucine-leucine (Leu-Leu-Leu), C18H35N3O4.
- leucine-leucine-leucine Leu-Leu-Leu
- C18H35N3O4 The chemical structure of trileucine is provided below:
- leucine refers to the amino acid leucine (C6H13NO2), which may be a racemic mixture or in either its D- or L-form, as well as modified forms of leucine (i.e. , where one or more atoms of leucine have been substituted with another atom or functional group).
- C6H13NO2 amino acid leucine
- modified forms of leucine i.e. , where one or more atoms of leucine have been substituted with another atom or functional group.
- the amounts of leucine and trileucine provided herein, unless otherwise stated, are provided as weight percentages (wt % or w/w %) of the formulations. As the dry powder formulations contain substantially little if any water, the weight components of the dry powder formulations are thus dry weight percentages of the final formulations.
- the dry powder formulation comprises about 10% to about 45% leucine by weight (w/w %) or about 20% to about 45% leucine by weight (w/w %). In some embodiments, the dry powder formulation comprises about 40% leucine by weight (w/w %).
- the dry powder formulation comprises about 2% to about 20% trileucine by weight (w/w %). In some embodiments, the dry powder formulation comprises about 20% trileucine by weight (w/w %).
- the leucine and trileucine are kept at a desired ratio range that provides the improved compressed bulk density characteristics described herein, as well as providing the desired microparticle characteristics that allow for improved storage and delivery.
- the weight ratio of leucine and trileucine in the microparticles i.e., Ieucine:trileucine, is about 0.01:1 to about 20:1.
- the weight ratio of leucine:trileucine in the microparticles is less than about 4:1. Increasing the amount of trileucine present in the formulation still further is likely to have beneficial effects in regards to moisture robustness and maintaining particle morphology while scaling up.
- the ratios described herein are expressed as ratios by weight% (w/w- also referred to as a “weight ratio” or w/w %), that is, weight of leucine:weight of trileucine in the formulations described herein.
- the ratios are achieved by providing a desired mg/mL concentration of leucine and trileucine in a feedstock, and then drying to remove the feedstock solvent resulting in an atomized microparticle where the starting concentration ratio (expressed in mg/mL), is maintained as a final ratio of leucine :trileucine by weight.
- Exemplary weight percentages for leucine and trileucine that can be utilized in the dry powder formulations to achieve these ratios are described herein.
- the dry powder formulations comprise about 5% to about 15% leucine by weight (w/w %) and about 1% to about 5% trileucine by weight (w/w %). In some embodiments, the dry powder formulations comprise about 8% to about 11% leucine by weight (w/w %) and about 2% to about 4% trileucine by weight (w/w %), and in some preferred embodiments, the dry powder formulations comprise about 10% leucine and about 2.6% trileucine by weight (w/w %).
- the use of the combination of leucine and trileucine in a dry powder formulation allows for the reduction in the overall amount of leucine and/or trileucine required to prepare microparticles, as compared to dry powder formulations that contain only one of these components, while still providing the desired stability. This helps to overcome the solubility limitations of trileucine and leucine and provides higher throughput.
- An exemplary process of preparing a dry powder formulation may take place as follows.
- a liquid feedstock containing the desired final components of the dry powder formulation are atomized using an atomizer, to a fine mist.
- the mist is then dried as described herein.
- the atomized droplets contain the dissolved components, initially as a liquid droplet.
- different components of the formulation begin to saturate and precipitate at varying rates.
- a shell begins to form around an outer surface of the microparticles of the dry powder formulations. This shell suitably includes the leucine and trileucine components at an outer surface of the shell.
- leucine and trileucine become preferentially located at an outer surface of the microparticles, while smaller amounts of leucine and trileucine can also found throughout the microparticles.
- a higher concentration of leucine and trileucine are suitably found at or near the surface of the microparticles, rather than near the center of the microparticles.
- the presence of leucine and trileucine at the surface of the microparticles may be analysed by Time-of-Flight Secondary Ion Mass Spectometry (ToF-SIMS).
- the center of the microparticles contain a substantial amount of the active agent, along with other excipient components as described herein, suitably in an amorphous form.
- a “substantial amount” of the active agent means at least about 60% of the active agent (i.e., of the total active agent in the formulation) is located at or near the center of the microparticles, suitably at least about 70%, and more suitably at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, and in embodiments about 95%-100%, of the active agent is located at or near the center of the microparticles.
- Exemplary buffering agents that can be included in the dry powder formulations include various phosphate buffers, citrate buffers (such as sodium citrate), a histidine buffer, a glycine buffer, an acetate buffer, and a tartrate buffer, as well as combinations of such buffers.
- the buffering agent is a phosphate buffer.
- the dry powder formulation includes potassium dihydrogen phosphate and anhydrous disodium phosphate.
- the dry powder formulation may comprise about 0.01% to 5% w/w buffer salt.
- the dry powder formulation may comprise about 0.01 % to 3% w/w buffer salt.
- Buffers also provide control of the pH of the dry powder formulations, suitably maintaining a pH of between about pH 5 and about 8, for example, about pH 5 to about pH 6, about pH 5.5 to about pH 6.5, about pH 6 to about pH 7, about pH 6.5 to about pH 7.5, or about pH 7 to about pH 8.
- compositions and formulations that “consist essentially” of the recited ingredients contain the recited components and those that do not materially affect the basic and novel characteristics of the claimed formulations.
- Components that do not materially affect the basic and novel characteristics of the claimed formulations are those that do not limit the ability of the leucine and trileucine to stabilize the dry powder formulations.
- compositions and formulations that consist essentially of the recited ingredients specifically exclude other amino acids or tripeptide amino acids, but can include additional sugars, buffers, etc.
- the dry powder formulations described herein comprise a tonicity agent, such as sodium chloride.
- the dry powder formulations comprise 0-15 w/w % sodium chloride.
- the dry powder formulations comprise about 0.4-15 w/w % sodium chloride.
- microparticles that make up the dry powder formulations described herein suitably have a specified mass median aerodynamic diameter (MMAD) when provided in aerosol form.
- MMAD mass median aerodynamic diameter
- MMAD mass median aerodynamic diameter
- the aerodynamic diameter is used to describe an aerosolized powder in terms of its settling behaviour and is the diameter of a unit density sphere having the same settling velocity, in air, as the microparticle.
- the aerodynamic diameter encompasses particle shape, density and physical size of a microparticle.
- MMAD refers to the midpoint or median of the aerodynamic particle size distribution of an aerosolized powder determined by cascade impaction, unless otherwise indicated.
- the microparticles of the dry powder formulations provided herein have a mass median aerodynamic diameter (MMAD) of at least 1 pm or greater, more suitably about 1 pm to about 10 pm, about 2 pm to about 8 pm, about 2 pm to about 7 pm, about 2 pm to about 6 pm, about 2 pm to about 5 pm, about 2 pm to about 4 pm, about 2 pm to about 3 pm, about 3 pm to about 4 pm, about 2 pm, or about 3 pm.
- MMAD mass median aerodynamic diameter
- the fine particle fraction (the fraction of particles emitted from an inhalation device having an aerodynamic particle diameter of less than 5 pm of the dry powder formulations) described herein is > 50%, more suitably > 60%.
- This fine particle fraction (FPF) may contribute to a low device retention of the dry powder formulations of less than 20%, suitably less than 15%, less than 10%, or less than 5%, remaining in a device following delivery to a patient.
- c From drug substance (AZDI 402) solution. Component amount will vary due to variation in protein concentration between drug substance batches.
- e Trehalose is charged as trehalose dihydrate in the manufacturing process, the water is removed during processing. 745 mg of trehalose corresponds to 822 mg trehalose dihydrate. Amount of trehalose will vary due to variation in buffer salt amounts coming from drug substance solution.
- the dry powder formulation of the invention comprises: an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO: 1 , or a variant or fragment thereof, trehalose, leucine and trileucine.
- the dry powder formulation further comprises a buffering agent, such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous disodium phosphate as a buffering agent, and/or a tonicity agent, such as sodium chloride.
- the dry powder formulation of the invention comprises: an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO: 1 , or a variant or fragment thereof, trehalose, leucine and trileucine, wherein said formulation provides a nominal delivered dose of about 0.5 mg, about 1mg, about 3mg, about 10mg or about 30mg of said lipocalin mutein, or variant or fragment thereof, when said formulation is administered to said subject by oral inhalation, wherein the formulation may further comprise a buffering agent, such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous disodium phosphate as a buffering agent, and/or a tonicity agent, such as sodium chloride.
- a buffering agent such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous disodium phosphate as a buffering agent, and/or
- the dry powder formulation of the invention comprises: an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO: 1 , or a variant or fragment thereof, trehalose, leucine and trileucine, wherein said formulation provides a nominal delivered dose of about 0.5 mg, about 1mg, about 2 mg, about 3mg, about 4mg, about 5mg, about 6 mg, about 10mg or about 30mg of said lipocalin mutein, or variant or fragment thereof, when said formulation is administered to said subject by oral inhalation, wherein the formulation may further comprise a buffering agent, such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous disodium phosphate as a buffering agent, and/or a tonicity agent, such as sodium chloride.
- a buffering agent such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or an
- the dry powder formulation of the invention comprises: an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO: 1, or a variant or fragment thereof, trehalose, leucine and trileucine, wherein said formulation provides a nominal delivered dose of about 2.5 mg, about 5mg, about 10 mg, about 15mg, about 20mg or about 25mg of said lipocalin mutein, or variant or fragment thereof, when said formulation is administered to said subject by oral inhalation, wherein the formulation may further comprise a buffering agent, such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous disodium phosphate as a buffering agent, and/or a tonicity agent, such as sodium chloride.
- a buffering agent such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous disodium phosphate as a buffering agent, and/
- the dry powder formulation of the invention comprises: an anti- IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO: 1, or a variant or fragment thereof, trehalose and leucine.
- the dry powder formulation further comprises a buffering agent, such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous disodium phosphate as a buffering agent, and/or a tonicity agent, such as sodium chloride.
- the dry powder formulation of the invention comprises: an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO: 1 , or a variant or fragment thereof, trehalose and leucine, wherein said formulation provides a nominal delivered dose of about 0.5 mg, about 1mg, about 3mg, about 10mg or about 30mg of said lipocalin mutein, or variant or fragment thereof, when said formulation is administered to said subject by oral inhalation, wherein the formulation may further comprise a buffering agent, such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous disodium phosphate as a buffering agent, and/or a tonicity agent, such as sodium chloride.
- a buffering agent such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous disodium phosphate as a buffering agent, and/or a tonicity agent
- the dry powder formulation of the invention comprises: an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO: 1, or a variant or fragment thereof, trehalose and leucine, wherein said formulation provides a nominal delivered dose of about 0.5 mg, about 1mg, about 2mg, about 3mg, about 4mg, about 5mg, about 6mg, about 10mg or about 30mg of said lipocalin mutein, or variant or fragment thereof, when said formulation is administered to said subject by oral inhalation, wherein the formulation may further comprise a buffering agent, such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous disodium phosphate as a buffering agent, and/or a tonicity agent, such as sodium chloride.
- a buffering agent such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous disodium
- the dry powder formulation of the invention comprises: an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO: 1, or a variant or fragment thereof, trehalose and leucine, wherein said formulation provides a nominal delivered dose of about 2.5 mg, about 5mg, about 10mg, about 15mg, about 20mg or about 25mg of said lipocalin mutein, or variant or fragment thereof, when said formulation is administered to said subject by oral inhalation, wherein the formulation may further comprise a buffering agent, such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous disodium phosphate as a buffering agent, and/or a tonicity agent, such as sodium chloride.
- a buffering agent such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous disodium phosphate as a buffering agent, and/or a tonic
- the dry powder formulation of the invention comprises: an anti- IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO: 1 , or a variant or fragment thereof, trehalose and trileucine.
- the dry powder formulation further comprises a buffering agent, such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous disodium phosphate as a buffering agent, and/or a tonicity agent, such as sodium chloride.
- the dry powder formulation of the invention comprises: an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO: 1, or a variant or fragment thereof, trehalose and trileucine, wherein said formulation provides a nominal delivered dose of about 0.5 mg, about 1mg, about 2mg, about 3mg, about 4mg, about 5mg, about 6mg, about 10mg or about 30mg of said lipocalin mutein, or variant or fragment thereof, when said formulation is administered to said subject by oral inhalation, wherein the formulation may further comprise a buffering agent, such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous disodium phosphate as a buffering agent, and/or a tonicity agent, such as sodium chloride.
- a buffering agent such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous diso
- the dry powder formulation of the invention comprises: an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO: 1, or a variant or fragment thereof, trehalose and trileucine, wherein said formulation provides a nominal delivered dose of about 2.5 mg, about 5mg, about 10mg, about 15mg, about 20mg or about 25mg of said lipocalin mutein, or variant or fragment thereof, when said formulation is administered to said subject by oral inhalation, wherein the formulation may further comprise a buffering agent, such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous disodium phosphate as a buffering agent, and/or a tonicity agent, such as sodium chloride.
- a buffering agent such as a phosphate buffer, e.g. potassium dihydrogen phosphate and/or anhydrous disodium phosphate as a buffering agent, and/or a
- Each of the individual components may be present in the amounts and/or ratios described herein.
- the dry powder formulation of the invention may be as shown in one of Tables 5-16 below, where AZD1402 is an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO: 1 , or a fragment or variant thereof.
- AZD1402 is an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO: 1 , or a fragment or variant thereof.
- Table 5 Composition of an exemplary formulation
- Table 6 Composition of an exemplary formulation
- Table 8 Composition of an exemplary formulation
- Table 9 Composition of an exemplary formulation
- Table 11 Composition of an exemplary formulation
- Table 12 Composition of an exemplary formulation
- Table 13 Composition of an exemplary formulation
- Table 14 Composition of an exemplary formulation
- Table 15 Composition of an exemplary formulation
- the dry powder formulation of the invention comprises: an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO: 1, or a variant or fragment thereof, trehalose, leucine and trileucine.
- the dry powder formulation further comprises a buffering agent, such as a phosphate buffer.
- the dry powder formulation comprises an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO: 1, or a variant or fragment thereof, trehalose and leucine.
- the dry powder formulation further comprises a buffering agent, such as a phosphate buffer.
- the dry powder formulation comprising the lipocalin mutein may be administered alone or in combination with other treatments, either simultaneously or sequentially.
- the lipocalin mutein may be administered in combination with corticosteroids, such as inhaled corticosteroids (ICS), long-acting beta 2 agonists (LABA) and/or long-acting muscarinic antagonists (LAMA).
- the lipocalin mutein may be administered in combination with low or medium dose ICS, inhaled LABA and/or inhaled LAMA.
- Low medium and high daily doses of ICS are described in the Pocket Guide for Asthma Management and Prevention, Global Initiative for Asthma, Updated 2020.
- systemic exposure means that a substantive portion of the inhaled lipocalin mutein enters the circulatory system and, optionally, that the entire body may be affected by the lipocalin mutein.
- Systemic exposure may mean that the amount of the lipocalin mutein that enters the circulatory system is quantifiable.
- Systemic exposure may equate to the concentration of lipocalin mutein that enters the bloodstream that is quantifiable. This exposure can be represented by the blood (serum, plasma or whole blood) concentration of the lipocalin mutein which can be measured over time and recorded by a range of parameters including the area under the curve (AUC).
- Systemic exposure to lipocalin mutein can also impact biomarkers, the levels of which can correlate directly to concentration of lipocalin mutein and therefore to systemic exposure.
- the term “quantifiable” or “detectable,” when used in connection with systemic exposure refers to the exposure represented by the blood (serum, plasma or whole blood) concentration of the lipocalin mutein or by the levels of biomarkers measurable by one or more analytical methods known in art.
- analytical methods include, but are not limited to, ELISA, competitive ELISA, fluorescence titration, calorimetric methods, mass spectrometry (MS), and chromatography methods, such as high-performance liquid chromatography (HPLC). It is also understood measurements performed using such analytical methods are associated with detection limits, such as instrument detection limit, method detection limits, and limit of quantification.
- systemic exposure to the lipocalin mutein was approximately 73-78% lower following administration of an nominal delivered dose of 18mg of the lipocalin mutein by inhalation of a nebulised formulation or administration of an nominal delivered dose to the lungs of 10mg of the lipocalin mutein by inhalation of a dry powder formulation than following administration of an nominal delivered dose to the lungs of 30mg of the lipocalin mutein by inhalation of a dry powder formulation.
- API active pharmaceutical ingredient
- T trehalose
- TL trehalose and leucine
- TLT trehalose, leucine and trileucine
- TT trehalose and trileucine
- the following example evaluates the aerosol performance of a formulation comprising AZD1402 and buffer salts in a dry powder inhaler device.
- the aerosol performance outputs listed in Table 19 were tested on a formulation with a ratio of AZD1402: PBS of not less than (NLT) 5.2:1.
- NLT Next Generation Impactor
- AZD 1402 was initially in a liquid formulation at a concentration of NLT 50 mg/ml.
- a feed stock solution was prepared at a total concentration of solids at 50 mg/mL by diluting AZD1402 solution with water.
- the feed solution was spray dried, using an outlet temperature of 65°C, feedstock feed rate, 1.85 ml/min; atomizer air, 2150 liters/hr; and drying gas flow, 23 kg/hr.
- the parameters were selected to achieve an acceptable water content and particle properties as well to maintain bioactivity for a dry powder formulation intended for inhalation.
- an enzyme linked immunosorbent assay (ELISA) is used to demonstrate the binding activity of AZD1402 to its specified target IL-4 receptor.
- the method is an antibody capture, antigen excess assay and relies on the fact that AZD1402 can be immobilised on to a 96 well plate coated with an antigen, recombinant human slL-4 alpha receptor.
- the immobilised AZD1402 is detected by adding a primary anti-AZD1402 antibody and subsequently a secondary anti-antibody labelled with a HRP enzyme is added.
- the HRP enzyme catalyses the reaction of a substrate to produce a coloured product.
- the amount of coloured product is directly proportional to the amount of secondary antibody present, which is in turn directly proportional to the amount of AZD1402 captured by the antigen.
- Standards of various known concentrations of AZD1402 are incubated with excess antigen and a calibration curve is constructed. The resulting log concentration versus absorbance response is plotted with a 4parameter logistic (4PL) curve fitting.
- the following example evaluates the aerosol performance of a formulation comprising trehalose in a dry powder inhaler device.
- the aerosol performance outputs listed in Table 22 were tested on a formulation with a drug load of 2 w/w% and a ratio of AZD1402: PBS of NLT 5.2:1 .
- AZD 1402 was initially in a liquid formulation at a concentration of NLT 50 mg/mL.
- a feed stock solution was prepared at a total concentration of solids at 40-50 mg/mL by first dissolving the trehalose in water and then adding into the AZD1402 solution.
- the feed solution was spray dried, using an outlet temperature of 65°C, feedstock feed rate 2.0 ml/min; atomizer air 2150 liters/hr; and drying gas flow 23 kg/hr.
- the parameters were selected to achieve an acceptable water content and particle properties as well to maintain bioactivity for a dry powder formulation intended for inhalation.
- Cascade impaction testing was performed as per USP ⁇ 601 > to measure the aerosol performance of the spray dried formulations when delivered from a dry powder inhaler device.
- the cascade impactor apparatus used was the Next Generation Impactor (NGI; USP41, Chapter ⁇ 601 >).
- NGI Next Generation Impactor
- one size 3 HPMC capsule containing 20 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the NGI at an airflow rate of 60 L/min as per USP methodology. Samples from each stage of the NGI were recovered and assayed for AZD1402 content.
- the following example evaluates the aerosol performance of a formulation comprising trehalose in a dry powder inhaler device.
- the aerosol performance outputs listed in Table 25 were tested on a formulation with a drug load of 60 w/w% and a ratio of AZD1402: PBS of NLT 5.2:1.
- AZD1402 was initially in a liquid formulation at a concentration of NLT 50 mg/mL.
- a feed stock solution was prepared at a total concentration of solids at 40-50 mg/mL by first dissolving the trehalose in water and then adding into the AZD1402 solution.
- the feed solution was spray dried, using an outlet temperature of 65°C, feedstock feed rate 2.0 ml/min; atomizer air 2150 liters/hr, and drying gas flow 23 kg/hr.
- the parameters were selected to achieve an acceptable water content and particle properties as well to maintain bioactivity for a dry powder formulation intended for inhalation.
- Cascade impaction testing was performed as per USP ⁇ 601 > to measure the aerosol performance of the spray dried formulations when delivered from a dry powder inhaler device.
- the cascade impactor apparatus used was the Next Generation Impactor (NGI; USP41, Chapter ⁇ 601 >).
- NGI Next Generation Impactor
- one size 3 HPMC capsule containing 20 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the NGI at an airflow rate of 60 L/min as per USP methodology. Samples from each stage of the NGI were recovered and assayed for AZD1402 content.
- the following example evaluates the aerosol performance of a formulation comprising trehalose and leucine in a dry powder inhaler device.
- the aerosol performance outputs listed in Table 28 were tested on a formulation with a drug load of 2 /w% and a ratio of AZD1402: PBS of NLT 5.2:1.
- AZD 1402 was initially in a liquid formulation at a concentration of NLT 50 mg/mL.
- a feed stock solution was prepared at a total concentration of solids at 50 mg/mL by first dissolving the leucine and trehalose in water and then adding into the AZD1402 solution.
- the feed solution was spray dried, using an outlet temperature of 65°C, feedstock feed rate 2.0 ml/min; atomizer air 2150 liters/hr, and drying gas flow 23 kg/hr.
- the parameters were selected to achieve an acceptable water content and particle properties as well to maintain bioactivity for a dry powder formulation intended for inhalation.
- Cascade impaction testing was performed as per USP ⁇ 601 > to measure the aerosol performance of the spray dried formulations when delivered from a dry powder inhaler device.
- the cascade impactor apparatus used was the Next Generation Impactor (NGI; USP41, Chapter ⁇ 601 >).
- NGI Next Generation Impactor
- one size 3 HPMC capsule containing 10 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the NGI at an airflow rate of 60 L/min as per USP methodology. Samples from each stage of the NGI were recovered and assayed for AZD1402 content.
- the delivered dose testing of the spray dried formulations when delivered from the Monodose dry powder inhaler device, was performed as per USP ⁇ 601 > while using a different dose collection unit.
- the powder aerosol is collected in a glass apparatus, an impinger, equipped with an inflatable inlet for tightness and a sintered glass filter (pore size 40 to 100 pm), (also described in Hugosson S, et al, Pharm Forum 1993;19(No 3):5458-5466.).
- one size 3 HPMC capsule containing 10 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the impinger at an airflow rate of 60 L/min (corresponding to a pressure drop of 4 kPa over the inhaler) as per USP methodology.
- a sample from the impinger is recovered and assayed for AZD1402 content.
- the following example evaluates the aerosol performance of a formulation comprising trehalose in a dry powder inhaler device.
- the aerosol performance outputs listed in Table 31 were tested on a formulation with a drug load of 60 w/w% and a ratio of AZD1402: PBS of NLT 5.2:1.
- Table 30 Composition of formulation
- AZD 1402 was initially in a liquid formulation at a concentration of NLT 50 mg/mL.
- a feed stock solution was prepared at a total concentration of solids at 40-50 mg/mL by first dissolving the trileucine and trehalose in water and then adding into the AZD1402 solution.
- the feed solution was spray dried using an outlet temperature of 65°C, feedstock feed rate 6.0 ml/min; atomizer air 6.5 kg/h; and drying gas flow 40 kg/hr.
- the parameters were selected to achieve an acceptable water content and particle properties as well to maintain bioactivity for a dry powder formulation intended for inhalation. This formulation had adequate chemical and physical stability, including bioactivity, and aerosol performance throughout the storage period at a time when sourcing of trileucine was an issue.
- Cascade impaction testing was performed as per USP ⁇ 601> to measure the aerosol performance of the spray dried formulations when delivered from a dry powder inhaler device.
- the cascade impactor apparatus used was the Next Generation Impactor (NGI; USP41, Chapter ⁇ 601 >).
- NGI Next Generation Impactor
- one size 3 HPMC capsule containing 20 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the NGI at an airflow rate of 60 L/min as per USP methodology. Samples from each stage of the NGI were recovered and assayed for AZD1402 content.
- the delivered dose testing of the spray dried formulations when delivered from the Monodose dry powder inhaler device, was performed as per USP ⁇ 601 > while using a different dose collection unit.
- the powder aerosol is collected in a glass apparatus, an impinger, equipped with an inflatable inlet for tightness and a sintered glass filter (pore size 40 to 100 pm), (also described in Hugosson S, et al, Pharm Forum 1993;19(No 3):5458-5466.).
- one size 3 HPMC capsule containing 20 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the impinger at an airflow rate of 60 L/min (corresponding to a pressure drop of 4 kPa over the inhaler) as per USP methodology.
- a sample from the impinger is recovered and assayed for AZD1402 content.
- the following example evaluates the aerosol performance of a formulation comprising trehalose in a dry powder inhaler device.
- the aerosol performance outputs listed in Table 34 were tested on a formulation with a drug load of 60 w/w% and a ratio of AZD1402: PBS of NLT 5.2:1.
- AZD 1402 was initially in a liquid formulation at a concentration of NLT 50 mg/mL.
- a feed stock solution was prepared at a total concentration of solids at 40 mg/mL by first dissolving the leucine and trehalose in water and then adding into the AZD1402 solution.
- the feed solution was spray dried using an outlet temperature of 65°C, feedstock feed rate 2.0 ml/min; atomizer air 2150 liters/hr, and drying gas flow 23 kg/hr. The parameters were selected to achieve an acceptable water content and particle properties as well to maintain bioactivity for a dry powder formulation intended for inhalation.
- Cascade impaction testing was performed as per USP ⁇ 601 > to measure the aerosol performance of the spray dried formulations when delivered from a dry powder inhaler device.
- the cascade impactor apparatus used was the Next Generation Impactor (NGI; USP41, Chapter ⁇ 601 >).
- NGI Next Generation Impactor
- one size 3 HPMC capsule containing 40 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the NGI at an airflow rate of 60 L/min as per USP methodology. Samples from each stage of the NGI were recovered and assayed for AZD1402 content.
- the delivered dose testing of the spray dried formulations when delivered from the Monodose dry powder inhaler device, was performed as per USP ⁇ 601 > while using a different dose collection unit.
- the powder aerosol is collected in a glass apparatus, an impinger, equipped with an inflatable inlet for tightness and a sintered glass filter (pore size 40 to 100 pm), (also described in Hugosson S, et al, Pharm Forum 1993;19(No 3):5458-5466.).
- one size 3 HPMC capsule containing 40 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the impinger at an airflow rate of 60 L/min (corresponding to a pressure drop of 4 kPa over the inhaler) as per USP methodology.
- a sample from the impinger is recovered and assayed for AZD1402 content.
- Bioactivity is measured against a reference sample and there is variability in the method.
- the following example evaluates the aerosol performance of a formulation comprising trehalose in a dry powder inhaler device.
- the aerosol performance outputs listed in Table 37 were tested on a formulation with a drug load of 2 w/w% and a ratio of AZD1402: PBS of NLT 5.2:1.
- AZD 1402 was initially in a liquid formulation at a concentration of NLT 50 mg/mL.
- a feed stock solution was prepared at a total concentration of solids at 50 mg/mL by first dissolving the leucine and trehalose in water and then adding into the AZD1402 solution.
- the feed solution was spray dried, using an outlet temperature of 65°C, feedstock feed rate 2.0 ml/min; atomizer air 2150 liters/hr, and drying gas flow 23 kg/hr.
- the parameters were selected to achieve an acceptable water content, particle properties and improved physical robustness, such as moisture resistance, as well to maintain bioactivity for a dry powder formulation intended for inhalation.
- Cascade impaction testing was performed as per USP ⁇ 601 > to measure the aerosol performance of the spray dried formulations when delivered from a dry powder inhaler device.
- the cascade impactor apparatus used was the Next Generation Impactor (NGI; USP41 , Chapter ⁇ 601 >).
- NGI Next Generation Impactor
- one size 3 HPMC capsule containing 10 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the NGI at an airflow rate of 60 L/min as per USP methodology. Samples from each stage of the NGI were recovered and assayed for AZD1402 content.
- the delivered dose testing of the spray dried formulations when delivered from the Monodose dry powder inhaler device, was performed as per USP ⁇ 601 > while using a different dose collection unit.
- the powder aerosol is collected in a glass apparatus, an impinger, equipped with an inflatable inlet for tightness and a sintered glass filter (pore size 40 to 100 pm), (also described in Hugosson S, et al, Pharm Forum 1993;19(No 3):5458-5466.).
- one size 3 HPMC capsule containing 10 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the impinger at an airflow rate of 60 L/min (corresponding to a pressure drop of 4 kPa over the inhaler) as per USP methodology.
- a sample from the impinger is recovered and assayed for AZD1402 content.
- EXAMPLE 8 AEROSOL PERFORMANCE CHARACTERISTICS OF 60 W/W% AZD1402 IN TREHALOSE-LEUCINE-TRILEUCINE FORMULATION
- the following example evaluates the aerosol performance of a formulation comprising trehalose in a dry powder inhaler device.
- the aerosol performance outputs listed in Table 40 were tested on a formulation with a drug load of 60 w/w% and a ratio of AZD1402: PBS of NLT 5.2:1.
- AZD 1402 was initially in a liquid formulation at a concentration of NLT 50 mg/mL.
- a feed stock solution was prepared at a total concentration of solids at 40 mg/mL by first dissolving the leucine and trehalose in water and then adding into the AZD1402 solution.
- the feed solution was spray dried, using an outlet temperature of 65°C, feedstock feed rate 2.0 ml/min; atomizer air 2150 liters/hr, and drying gas flow 23 kg/hr.
- the parameters were selected to achieve an acceptable water content, particle properties and improved physical robustness, such as moisture resistance, as well to maintain bioactivity for a dry powder formulation intended for inhalation.
- Cascade impaction testing was performed as per USP ⁇ 601 > to measure the aerosol performance of the spray dried formulations when delivered from a dry powder inhaler device.
- the cascade impactor apparatus used was the Next Generation Impactor (NGI; USP41, Chapter ⁇ 601 >).
- NGI Next Generation Impactor
- one size 3 HPMC capsule containing 40 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the NGI at an airflow rate of 60 L/min as per USP methodology. Samples from each stage of the NGI were recovered and assayed for AZD1402 content.
- the delivered dose testing of the spray dried formulations when delivered from the Monodose dry powder inhaler device, was performed as per USP ⁇ 601 > while using a different dose collection unit.
- the powder aerosol is collected in a glass apparatus, an impinger, equipped with an inflatable inlet for tightness and a sintered glass filter (pore size 40 to 100 pm), (also described in Hugosson S, et al, Pharm Forum 1993;19(No 3):5458-5466.).
- one size 3 HPMC capsule containing 40 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the impinger at an airflow rate of 60 L/min (corresponding to a pressure drop of 4 kPa over the inhaler) as per USP methodology.
- a sample from the impinger is recovered and assayed for AZD1402 content.
- EXAMPLE 9 AEROSOL PERFORMANCE CHARACTERISTICS OF 11 W/W% AZD1402 IN TREHALOSE-LEUCINE-TRILEUCINE FORMULATION
- the aerosol performance outputs listed in Table 43 were tested on a formulation with a drug load of 11 w/w% and a ratio of AZD1402: PBS of NLT 5.2:1.
- AZD 1402 was initially in a liquid formulation at a concentration of NLT 50 mg/mL.
- a feed stock solution was prepared at a total concentration of solids at 50 mg/mL by first dissolving the leucine and trehalose in water and then adding into the AZD1402 solution.
- the feed solution was spray dried using an outlet temperature of 65°C, feedstock feed rate, 6.0 ml/min; atomizer gas 9,5 kg/h; and drying gas flow 40 kg/hr.
- the parameters were selected to achieve an acceptable, particle properties and improved physical robustness, such as moisture resistance, as well to maintain bioactivity for a dry powder formulation intended for inhalation. This formulation displayed good aerosol performance, improved physical robustness, such as moisture resistance, bioactivity and was physically and chemically stable throughout the storage period.
- Cascade impaction testing was performed as per USP ⁇ 601 > to measure the aerosol performance of the spray dried formulations when delivered from a dry powder inhaler device.
- the cascade impactor apparatus used was the Next Generation Impactor (NGI; USP41, Chapter ⁇ 601 >).
- NGI Next Generation Impactor
- one size 3 HPMC capsule containing 10 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the NGI at an airflow rate of 60 L/min as per USP methodology. Samples from each stage of the NGI were recovered and assayed for AZD1402 content.
- the delivered dose testing of the spray dried formulations when delivered from the Monodose dry powder inhaler device, was performed as per USP ⁇ 601 > while using a different dose collection unit.
- the powder aerosol is collected in a glass apparatus, an impinger, equipped with an inflatable inlet for tightness and a sintered glass filter (pore size 40 to 100 pm), (also described in Hugosson S, et al, Pharm Forum 1993;19(No 3):5458-5466.).
- one size 3 HPMC capsule containing 10 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the impinger at an airflow rate of 60 L/min (corresponding to a pressure drop of 4 kPa over the inhaler) as per USP methodology.
- a sample from the impinger is recovered and assayed for AZD1402 content.
- the following example evaluates the aerosol performance of a formulation comprising trehalose in a dry powder inhaler device.
- the aerosol performance outputs listed in Table 46 were tested on a formulation with a drug load of 33 w/w% and a ratio of AZD1402: PBS of NLT 5.2:1.
- AZD 1402 was initially in a liquid formulation at a concentration of NLT 50 mg/mL.
- a feed stock solution was prepared at a total concentration of solids at 50 mg/mL by first dissolving the leucine and trehalose in water and then adding into the AZD1402 solution.
- the feed solution was spray dried using an outlet temperature of 65°C, feedstock feed rate, 6.0 ml/min; atomizer gas 9.5 kg/h; and drying gas flow 40 kg/hr.
- the parameters were selected to achieve an acceptable water content and particle properties as well to maintain bioactivity for a dry powder formulation intended for inhalation.
- This formulation displayed good aerosol performance, improved physical robustness, such as moisture resistance, bioactivity and was physically and chemically stable throughout the storage period. Data from physical powder characteristics attributes are listed in Table 46.
- Cascade impaction testing was performed as per USP ⁇ 601 > to measure the aerosol performance of the spray dried formulations when delivered from a dry powder inhaler device.
- the cascade impactor apparatus used was the Next Generation Impactor (NGI; USP41, Chapter ⁇ 601 >).
- NGI Next Generation Impactor
- one size 3 HPMC capsule containing 10 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the NGI at an airflow rate of 60 L/min as per USP methodology. Samples from each stage of the NGI were recovered and assayed for AZD1402 content.
- the delivered dose testing of the spray dried formulations when delivered from the Monodose dry powder inhaler device, was performed as per USP ⁇ 601 > while using a different dose collection unit.
- the powder aerosol is collected in a glass apparatus, an impinger, equipped with an inflatable inlet for tightness and a sintered glass filter (pore size 40 to 100 pm), (also described in Hugosson S, et al, Pharm Forum 1993;19(No 3):5458-5466.).
- one size 3 HPMC capsule containing 10 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the impinger at an airflow rate of 60 L/min (corresponding to a pressure drop of 4 kPa over the inhaler) as per USP methodology.
- a sample from the impinger is recovered and assayed for AZD1402 content.
- Bioactivity is measured against a reference sample and there is variability in the method.
- the following example evaluates the aerosol performance of a formulation comprising trehalose in a dry powder inhaler device.
- the aerosol performance outputs listed in Table 49 were tested on a formulation with a drug load of 60 w/w% and a ratio of AZD1402: PBS of NLT 5.2:1.
- Table 48 Composition of formulation AZD 1402 was initially in a liquid formulation at a concentration of NLT 50 mg/mL.
- a feed stock solution was prepared at a total concentration of solids at 50 mg/mL by first dissolving the leucine, trileucine and trehalose in water and then adding into the AZD1402 solution.
- the feed solution was spray dried using an outlet temperature of 65°C, feedstock feed rate, 6.0 ml/min; atomizer gas 9.5 kg/h; and drying gas flow 40 kg/hr.
- the parameters were selected to achieve an acceptable water, particle properties and improved physical robustness, such as moisture resistance, as well to maintain bioactivity for a dry powder formulation intended for inhalation.
- This formulation displayed good aerosol performance, improved physical robustness, such as moisture resistance, bioactivity and was physically and chemically stable throughout the storage period.
- Cascade impaction testing was performed as per USP ⁇ 601> to measure the aerosol performance of the spray dried formulations when delivered from a dry powder inhaler device.
- the cascade impactor apparatus used was the Next Generation Impactor (NGI; USP41, Chapter ⁇ 601 >).
- NGI Next Generation Impactor
- one size 3 HPMC capsule containing 18.5 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the NGI at an airflow rate of 60 L/min as per USP methodology. Samples from each stage of the NGI were recovered and assayed for AZD1402 content.
- the delivered dose testing of the spray dried formulations when delivered from the Monodose dry powder inhaler device, was performed as per USP ⁇ 601> while using a different dose collection unit.
- the powder aerosol is collected in a glass apparatus, an impinger, equipped with an inflatable inlet for tightness and a sintered glass filter (pore size 40 to 100 pm), (also described in Hugosson S, et al, Pharm Forum 1993;19(No 3):5458-5466.).
- one size 3 HPMC capsule containing 18.5 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the impinger at an airflow rate of 60 L/min (corresponding to a pressure drop of 4 kPa over the inhaler) as per USP methodology.
- a sample from the impinger is recovered and assayed for AZD1402 content.
- EXAMPLE 12 AEROSOL PERFORMANCE CHARACTERISTICS OF 5 W/W% AZD1402 IN 3W/W% TRILEUCINE FORMULATION
- the following example evaluates the aerosol performance of a formulation comprising trehalose in a dry powder inhaler device.
- the aerosol performance outputs listed in Table 52 were tested on a formulation with a drug load of 5 w/w% and a ratio of AZD1402: PBS of NLT 5.2:1.
- AZD 1402 was initially in a liquid formulation at a concentration of NLT 50 mg/mL.
- a feed stock solution was prepared at a total concentration of solids at 50 mg/mL by first dissolving the trileucine and trehalose in water and then adding into the AZD1402 solution.
- the feed solution was spray dried using an outlet temperature of 65°C, feedstock feed rate 2.0 ml/min; atomizer air 2150 liters/hr; and drying gas flow 23 kg/hr.
- the parameters were selected to achieve an acceptable water content, particle properties and improved physical robustness, such as moisture resistance, as well to maintain bioactivity, for a dry powder formulation intended for inhalation.
- Cascade impaction testing was performed as per USP ⁇ 601 > to measure the aerosol performance of the spray dried formulations when delivered from a dry powder inhaler device.
- the cascade impactor apparatus used was the Next Generation Impactor (NGI; USP41 , Chapter ⁇ 601 >).
- NGI Next Generation Impactor
- one size 3 HPMC capsule containing 10 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the NGI at an airflow rate of 60 L/min as per USP methodology. Samples from each stage of the NGI were recovered and assayed for AZD1402 content.
- the delivered dose testing of the spray dried formulations when delivered from the Monodose dry powder inhaler device, was performed as per USP ⁇ 601 > while using a different dose collection unit.
- the powder aerosol is collected in a glass apparatus, an impinger, equipped with an inflatable inlet for tightness and a sintered glass filter (pore size 40 to 100 pm), (also described in Hugosson S, et al, Pharm Forum 1993;19(No 3):5458-5466.).
- one size 3 HPMC capsule containing 10 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the impinger at an airflow rate of 60 L/min (corresponding to a pressure drop of 4 kPa over the inhaler) as per USP methodology.
- a sample from the impinger is recovered and assayed for AZD1402 content.
- the following example evaluates the aerosol performance of a formulation comprising trehalose in a dry powder inhaler device.
- the aerosol performance outputs listed in Table 55 were tested on a formulation with a drug load of 5 w/w% and a ratio of AZD1402: PBS of NLT 5.2:1.
- Table 54 Composition of formulation
- AZD 1402 was initially in a liquid formulation at a concentration of NLT 50 mg/mL.
- a feed stock solution was prepared at a total concentration of solids at 50 mg/mL by first dissolving the trileucine and trehalose in water and then adding into the AZD1402 solution.
- the feed solution was spray dried, using an outlet temperature of 65°C, feedstock feed rate 2.0 ml/min; atomizer air 2150 liters/hr; and drying gas flow 23 kg/hr.
- the parameters were selected to achieve an acceptable water content, particle properties and improved physical robustness, such as moisture resistance, as well to maintain bioactivity, for a dry powder formulation intended for inhalation.
- Cascade impaction testing was performed as per USP ⁇ 601 > to measure the aerosol performance of the spray dried formulations when delivered from a dry powder inhaler device.
- the cascade impactor apparatus used was the Next Generation Impactor (NGI; USP41, Chapter ⁇ 601 >).
- NGI Next Generation Impactor
- one size 3 HPMC capsule containing 10 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the NGI at an airflow rate of 60 L/min as per USP methodology. Samples from each stage of the NGI were recovered and assayed for AZD1402 content.
- the delivered dose testing of the spray dried formulations when delivered from the Monodose dry powder inhaler device, was performed as per USP ⁇ 601> while using a different dose collection unit.
- the powder aerosol is collected in a glass apparatus, an impinger, equipped with an inflatable inlet for tightness and a sintered glass filter (pore size 40 to 100 pm), (also described in Hugosson S, et al, Pharm Forum 1993;19(No 3):5458-5466.).
- one size 3 HPMC capsule containing 10 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the impinger at an airflow rate of 60 L/min (corresponding to a pressure drop of 4 kPa over the inhaler) as per USP methodology.
- a sample from the impinger is recovered and assayed for AZD1402 content.
- the following example evaluates the aerosol performance of a formulation comprising trehalose, leucine and trileucine in a dry powder inhaler device.
- the aerosol performance outputs listed in Table 58 were tested on a formulation with a drug load of 10 w/w% and a ratio of AZD1402: Histidine of NLT 4.1 :1.
- AZD 1402 was initially in a liquid formulation at a concentration of NLT 50 mg/mL.
- a feed stock solution was prepared at a total concentration of solids at 50 mg/mL by first dissolving the leucine and trehalose in water and then adding into the AZD1402 solution.
- the feed solution was spray dried using an outlet temperature of 65°C, feedstock feed rate, 6.0 ml/min; atomizer gas 9,5 kg/h; and drying gas flow 40 kg/hr.
- the parameters were selected to achieve an acceptable, particle properties and improved physical robustness, such as moisture resistance, as well to maintain bioactivity for a dry powder formulation intended for inhalation. This formulation displayed good aerosol performance, improved physical robustness, such as moisture resistance, bioactivity and was physically and chemically stable throughout the storage period.
- Cascade impaction testing was performed as per USP ⁇ 601 > to measure the aerosol performance of the spray dried formulations when delivered from a dry powder inhaler device.
- the cascade impactor apparatus used was the Next Generation Impactor (NGI; USP41, Chapter ⁇ 601 >).
- NGI Next Generation Impactor
- one size 3 HPMC capsule containing 10 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the NGI at an airflow rate of 60 L/min as per USP methodology. Samples from each stage of the NGI were recovered and assayed for AZD1402 content.
- the delivered dose testing of the spray dried formulations when delivered from the Monodose dry powder inhaler device, was performed as per USP ⁇ 601 > while using a different dose collection unit.
- the powder aerosol is collected in a glass apparatus, an impinger, equipped with an inflatable inlet for tightness and a sintered glass filter (pore size 40 to 100 pm), (also described in Hugosson S, et al, Pharm Forum 1993;19(No 3):5458-5466.).
- one size 3 HPMC capsule containing 10 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the impinger at an airflow rate of 60 L/min (corresponding to a pressure drop of 4 kPa over the inhaler) as per USP methodology.
- a sample from the impinger is recovered and assayed for AZD1402 content.
- the following example evaluates the aerosol performance of a formulation comprising trehalose, leucine and trileucine in a dry powder inhaler device.
- the aerosol performance outputs listed in Table 61 were tested on a formulation with a drug load of 50 w/w% and a ratio of AZD1402: Histidine of NLT 4.1 :1.
- AZD 1402 was initially in a liquid formulation at a concentration of NLT 50 mg/mL.
- a feed stock solution was prepared at a total concentration of solids at 50 mg/mL by first dissolving the leucine and trehalose in water and then adding into the AZD1402 solution.
- the feed solution was spray dried using an outlet temperature of 65°C, feedstock feed rate, 6.0 ml/min; atomizer gas 9,5 kg/h; and drying gas flow 40 kg/hr.
- the parameters were selected to achieve an acceptable, particle properties and improved physical robustness, such as moisture resistance, as well to maintain bioactivity for a dry powder formulation intended for inhalation.
- This formulation displayed good aerosol performance, improved physical robustness, such as moisture resistance, bioactivity and was physically and chemically stable throughout the storage period. Data from physical powder characteristics attributes are listed in Table 61.
- Cascade impaction testing was performed as per USP ⁇ 601 > to measure the aerosol performance of the spray dried formulations when delivered from a dry powder inhaler device.
- the cascade impactor apparatus used was the Next Generation Impactor (NGI; USP41, Chapter ⁇ 601 >).
- NGI Next Generation Impactor
- one size 3 HPMC capsule containing 18.5 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the NGI at an airflow rate of 60 L/min as per USP methodology. Samples from each stage of the NGI were recovered and assayed for AZD1402 content.
- the delivered dose testing of the spray dried formulations when delivered from the Monodose dry powder inhaler device, was performed as per USP ⁇ 601 > while using a different dose collection unit.
- the powder aerosol is collected in a glass apparatus, an impinger, equipped with an inflatable inlet for tightness and a sintered glass filter (pore size 40 to 100 pm), (also described in Hugosson S, et al, Pharm Forum 1993;19(No 3):5458-5466.).
- one size 3 HPMC capsule containing 18.5 mg of the spray dried powder formulation was dispersed from the dry powder inhaler device and delivered into the impinger at an airflow rate of 60 L/min (corresponding to a pressure drop of 4 kPa over the inhaler) as per USP methodology.
- a sample from the impinger is recovered and assayed for AZD1402 content.
- Example 16 A Randomized Open-label, 3-period, 3-treatment, Crossover Study to Assess the Effect of Inhalation Device and Formulation on Pharmacokinetics Following a Single Inhaled Dose of AZD1402 in Healthy Subjects
- This study was intended to assess the effect of an inhalation powder (delivered via the Plastiape Monodose inhaler) on the PK characteristics of AZD1402 and to compare it to the nebulizer solution (delivered via the InnoSpire Go) that has been administered in studies conducted to date.
- the study results provide information on the PK profile of the study material to be used in further clinical development. Since PK assessments were the primary objective, an open-label design was selected. The study was conducted in healthy subjects to minimise the effects of concomitant disease states or medications on study measurements. Subjects received all 3 test products in a randomized order.
- test product A The InnoSpire Go nebulizer nominal delivered dose of 18 mg (test product A) was selected since it was safe and well-tolerated in the studies conducted to date, clinically relevant for the future development program and provided measurable serum concentrations up to 18 hours.
- the Plastiape Monodose dry powder inhaler (DPI) nominal delivered dose of 10 mg was selected to deliver an equivalent lung dose to Treatment A of 9 mg (based on calculated nebulizer and DPI inhalation device efficiencies).
- the Plastiape Monodose inhaler nominal delivered dose of 30 mg was selected to evaluate the dose proportionality of the inhalation formulation and Plastiape Monodose inhaler device.
- the selected doses were well below the InnoSpire Go nebulizer nominal delivered doses of up to 160 mg that have been administered to healthy subjects in a single ascending dose study and which were safe and well tolerated (NCT03384290).
- This study was a randomized, open-label, 3-period, 3-treatment, single-dose, single-centre, crossover study. Eighteen healthy male and female subjects were to be randomized in this study to ensure that at least 12 subjects were evaluable. A subject was considered to be evaluable if the subject completed all 3 Treatment Periods with no important protocol deviations. Each subject received all 3 doses of the IMP; no placebo was used in this study.
- Subjects were randomized to 1 of 6 treatment sequences and received the 3 single dose test products of AZD1402 listed below.
- Test product A 18 mg nominal delivered dose of AZD1402 nebulizer solution administered via the InnoSpire Go nebulizer.
- Test product B 10 mg nominal delivered dose of AZD1402 inhalation powder administered via a Plastiape Monodose inhaler.
- Test product C 30 mg nominal delivered dose of AZD1402 inhalation powder administered via a Plastiape Monodose inhaler.
- Treatment Period was separated by a minimum washout period of 5 days between doses. All subjects signed an ICF before they participated in any specific study related procedures. Subjects attended a Screening Visit within 28 days before receiving their first dose of AZD1402. If they were eligible, they returned for Treatment Period 1 when they had baseline assessments and received 1 of 3 test products in a randomized order. For each Treatment Period, the subjects received a single dose of IMP in the morning of Day 1 and had further assessments for 48 hours after dosing.
- AZD1402 was administered as a nebulizer solution via the InnoSpire Go nebulizer for test product A (Treatment A) and as an inhalation powder via a Plastiape Monodose inhaler for test product B (Treatment B) and test product C (Treatment C).
- the dose was administered after an overnight fast of at least 10 hours. Subjects were allowed to drink water to prevent dehydration until 1 hour before IMP administration. Water was allowed ad libitum from 1 hour after IMP administration and a light breakfast was provided 2 hours after IMP administration. All subjects received the test products in a randomized sequence.
- IMPs Investigational Medicinal Products
- Treatment C had a positive pre-dose concentration of 1.54 ng/ml_. This concentration was ⁇ 5% C max and was excluded from PK analysis.
- AZD1402 Following inhalation of AZD1402 either via nebulizer (Treatment A, 18 mg delivered dose) or Plastiape Monodose Inhaler (Treatment B, 10 mg delivered dose or Treatment C, 30 mg delivered dose) a sustained and relatively prolonged absorption was observed with a similar median tmax of 3.00 to 3.50 h. Individual tmax ranged from 1.98 to 8.27 h and the ranges were similar across all three treatments.
- Inter-subject variability in AZD1402 was moderate to high for AUC (48.79%, 35.84% and 62.74% for Treatments A, B and C respectively), high for AUC test (51.86%, 57.71% and 68.69% for Treatments A, B and C respectively) and high for C max (101.1%, 47.76% and 67.82% for Treatments A, B and C respectively).
- Exposure (C max , AUC, and AUC test ) following Treatment A was approximately 27% of that after Treatment C: geometric LS mean ratio (90% Cl) was 27.47% (18.90, 39.94), 27.09% (20.25, 36.24), and 26.50% (19.40, 36.20) for C max , AUC, and AUC test , respectively.
- Exposure (C max , AUC, and AUC test ) following Treatment B was approximately 22-26% of that after Treatment C: geometric LS mean ratio (90%CI) was 26.05% (18.03, 37.64), 26.46% (19.72, 35.50), and 21.68% (16.04, 29.32) for C max , AUC, and AUC test , respectively.
- AUC area under the serum concentration-time curve from time zero extrapolated to infinity
- AUC/D area under the serum concentration-time curve from time zero extrapolated to infinity divided by dose
- AUC test area under the serum concentration-curve from time zero to time of last quantifiable concentration
- AUC test /D area under the serum concentration-curve from time zero to time of last quantifiable concentration divided by dose
- C max maximum observed serum concentration
- C max /D maximum observed serum concentration divided by dose
- tmax time to reach maximum observed concentration
- t1 ⁇ 2 ⁇ z half-life terminal associated with the terminal slope (Az) of a semi-logarithmic concentration time curve
- Az terminal elimination rate constant
- MRT mean residence time of the unchanged drug in the systemic circulation from zero to infinity
- CL/F apparent total body clearance of the drug from serum after extravascular administration
- Vz/F apparent volume of distribution during the terminal phase after extravascular administration.
- Table 67 summarises AEs reported for the 3 single dose treatments: A (18 mg once daily), B (10 mg once daily) and C (30 mg once daily), and overall.
- the most frequently reported TEAEs (>2 subjects) by preferred term were cough (2 subjects with episodes reported while on Treatment A, 1 while on Treatment B and 4 while on Treatment C) and headache (2 subjects each with episodes reported while on Treatment A and Treatment B, and 1 while on Treatment C).
- SUSAR serious adverse reaction
- AZD1402 administered by inhalation in a DPI form is safe in healthy volunteers and merits further testing in patients having lung disease, e.g. asthma.
- AZD1402 is a recombinant, monospecific, Anticalin® (modified lipocalin) protein targeting the interleukin 4 receptor alpha (IL-4Ra) and is being developed as inhaled therapy for the treatment of moderate to severe persistent asthma for patients that are not controlled on standard of care therapies. This was a randomized open-label, 3-period, 3-treatment, crossover study to assess the effect of inhalation device and formulation on PK following a single inhaled dose of AZD1402 in healthy subjects.
- Anticalin® modified lipocalin
- the selected doses (InnoSpire Go nebulizer nominal delivered dose of 18 mg [Treatment A], Plastiape Monodose inhaler nominal delivered dose of 10 mg [Treatment B), and Plastiape Monodose inhaler nominal delivered dose of 30 mg [Treatment C]) were well below the InnoSpire Go nebulizer nominal delivered doses of up to 160 mg that have been administered to healthy subjects in a SAD study (PRS-060-PCS_06_17) and that were safe and well tolerated.
- Example 17 A Two-part Phase Ila Randomised, Double-blind, Placebo-controlled, Doseranging, Multicentre Study to Assess Efficacy and Safety of Three Inhaled Dose Levels of AZD1402 Administered as a Dry Powder Twice Daily for Four Weeks in Adults with Asthma on Medium Dose Inhaled Corticosteroids
- Part 1 will be performed in a lead-in cohort for each dose level to evaluate the safety and pharmacokinetic (PK) in a population with asthma controlled on medium dose inhaled corticosteroids (ICS)-long acting beta agonists (LABA) before progressing to dosing in adults with asthma who are uncontrolled on medium dose ICS- LABA in Part 2.
- Part 2 will be initiated for each dose level following evaluation of safety and PK at the relevant dose level in Part 1.
- the entire study period for each participant in both Parts 1 and 2 is approximately 3.5 months; a 2-week Screening Period, a 4 week Run-in Period, 4 weeks of Treatment Period, and 4 weeks of Follow-Up Period.
- Part 1 of the study will be randomised, double blind, placebo-controlled, and conducted in parallel for the 2 lower dose levels (Part 1a) followed by an unblinded safety review and escalation to the highest dose (Part 1b) dependent on the outcome of the safety review.
- Part 1a will consist of 30 participants who will be randomised 1:1 :1 to receive 1 of the 2 lower AZD1402 dry power inhaler (DPI) doses (1 or 3 mg nominal delivered doses) or placebo in parallel.
- Part 1b will consist of 15 participants who will be randomised 2:1 to receive the highest AZD1402 DPI dose (10 mg nominal delivered dose) or placebo.
- DPI dry power inhaler
- Part 1 a lead-in cohort
- Part 2 will be randomised, double blind, placebo controlled and will include 360 participants to evaluate 3 inhaled dose levels of AZD1402 versus placebo.
- Part 2a which includes the 2 lower dose levels (1 and 3 mg nominal delivered doses) will be started in parallel after the unblinded safety review for Part 1a.
- Part 2b The higher dose of 10 mg nominal delivered dose (Part 2b) will be included in Part 2 following the unblinded review of Part 1b, depending on the outcome of the safety review.
- Part 2b all 3 dose levels (and placebo) will run in parallel.
- Part 2 will include:
- the intravenous (i.v.) exposure data from the single dose study NCT03384290 (described in Example 2 of WO 2020/200960) was fitted to a 2-compartment pharmacokinetic model using Nonmem (version 7.3.0).
- the absorption rate of inhaled AZD1402 from the lung was subsequently modelled based on inhaled exposure data from studies NCT03384290 (single ascending dose (SAD) study described in Example 2 of WO 2020/200960), NCT03574805 (multiple ascending dose (MAD) study described in Examples 3 and 4 of WO 2020/200960) and NCT03921268, which is described in Example 16 above.
- a method for treating asthma in a human subject comprising administering by inhalation a dry powder formulation comprising a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO: 1, or a variant or fragment thereof, to said subject, wherein a nominal delivered dose of about 0. Img to about 30mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject by oral inhalation.
- IL-4Ra anti-IL-4 receptor alpha
- a method for treating asthma in a human subject comprising administering by inhalation a dry powder formulation comprising a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO: 1, or a variant or fragment thereof, to said subject, wherein a nominal metered dose of about 0.2mg to about 40mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject by oral inhalation.
- IL-4Ra anti-IL-4 receptor alpha
- a dry powder formulation comprising a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein, or a variant or fragment thereof, for use in a method for treatment of asthma in a human subject, wherein the method comprises administering the dry powder formulation by inhalation, wherein a nominal delivered dose of about O.lmg to about 30mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject by oral inhalation, and wherein the anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprises the amino acid sequence set forth in SEQ ID NO: 1, or a variant or fragment thereof. 17.
- a dry powder formulation comprising a therapeutically effective amount of an anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein, or a variant or fragment thereof, for use in a method for treatment of asthma in a human subject, wherein the method comprises administering the dry powder formulation by inhalation, wherein a nominal metered dose of about 0.2mg to about 40mg of said lipocalin mutein, or variant or fragment thereof, is administered to said subject by oral inhalation, and wherein the anti-IL-4 receptor alpha (IL-4Ra) lipocalin mutein comprises the amino acid sequence set forth in SEQ ID NO: 1, or a variant or fragment thereof.
- a dry powder formulation wherein said formulation comprises an anti-IL-4 receptor alpha (IL- 4Ra) lipocalin mutein comprising the amino acid sequence set forth in SEQ ID NO: 1, or a variant or fragment thereof.
- IL- 4Ra anti-IL-4 receptor alpha
- a method for treating asthma in a human subject comprising administering by oral inhalation the dry powder formulation according to any one of clauses 31-40.
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180085274.3A CN116916945A (en) | 2020-12-18 | 2021-12-20 | Lipocalin mutein dry powder formulation for treating asthma |
AU2021399151A AU2021399151A1 (en) | 2020-12-18 | 2021-12-20 | Lipocalin mutein dry powder formulation for treatment of asthma |
EP21844230.9A EP4262845A1 (en) | 2020-12-18 | 2021-12-20 | Lipocalin mutein dry powder formulation for treatment of asthma |
KR1020237023191A KR20230121785A (en) | 2020-12-18 | 2021-12-20 | Lipocalin mutein dry powder formulation for the treatment of asthma |
CR20230265A CR20230265A (en) | 2020-12-18 | 2021-12-20 | Lipocalin mutein dry powder formulation for treatment of asthma |
IL303729A IL303729A (en) | 2020-12-18 | 2021-12-20 | Lipocalin mutein dry powder formulation for treatment of asthma |
CA3199479A CA3199479A1 (en) | 2020-12-18 | 2021-12-20 | Lipocalin mutein dry powder formulation for treatment of asthma |
JP2023536889A JP2023553703A (en) | 2020-12-18 | 2021-12-20 | Lipocalin mutein dry powder formulation for the treatment of asthma |
CONC2023/0007904A CO2023007904A2 (en) | 2020-12-18 | 2023-06-16 | Lipocalin Mutein Dry Powder Formulation for the Treatment of Asthma |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063127903P | 2020-12-18 | 2020-12-18 | |
US63/127,903 | 2020-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022129629A1 true WO2022129629A1 (en) | 2022-06-23 |
Family
ID=79686778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2021/086730 WO2022129629A1 (en) | 2020-12-18 | 2021-12-20 | Lipocalin mutein dry powder formulation for treatment of asthma |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP4262845A1 (en) |
JP (1) | JP2023553703A (en) |
KR (1) | KR20230121785A (en) |
CN (1) | CN116916945A (en) |
AR (1) | AR124436A1 (en) |
AU (1) | AU2021399151A1 (en) |
CA (1) | CA3199479A1 (en) |
CL (1) | CL2023001775A1 (en) |
CO (1) | CO2023007904A2 (en) |
CR (1) | CR20230265A (en) |
IL (1) | IL303729A (en) |
TW (1) | TW202241490A (en) |
WO (1) | WO2022129629A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005019256A2 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
WO2008015239A2 (en) | 2006-08-01 | 2008-02-07 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
WO2011154420A2 (en) | 2010-06-08 | 2011-12-15 | Pieris Ag | Tear lipocalin muteins binding il-4 r alpha |
WO2013087660A1 (en) | 2011-12-13 | 2013-06-20 | Pieris Ag | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
WO2020201038A1 (en) * | 2019-03-29 | 2020-10-08 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
WO2020200960A1 (en) | 2019-03-29 | 2020-10-08 | Astrazeneca Ab | Lipocalin mutein for treatment of asthma |
-
2021
- 2021-12-20 EP EP21844230.9A patent/EP4262845A1/en active Pending
- 2021-12-20 AR ARP210103583A patent/AR124436A1/en unknown
- 2021-12-20 IL IL303729A patent/IL303729A/en unknown
- 2021-12-20 CN CN202180085274.3A patent/CN116916945A/en active Pending
- 2021-12-20 JP JP2023536889A patent/JP2023553703A/en active Pending
- 2021-12-20 CR CR20230265A patent/CR20230265A/en unknown
- 2021-12-20 CA CA3199479A patent/CA3199479A1/en active Pending
- 2021-12-20 AU AU2021399151A patent/AU2021399151A1/en active Pending
- 2021-12-20 KR KR1020237023191A patent/KR20230121785A/en unknown
- 2021-12-20 TW TW110147707A patent/TW202241490A/en unknown
- 2021-12-20 WO PCT/EP2021/086730 patent/WO2022129629A1/en active Application Filing
-
2023
- 2023-06-15 CL CL2023001775A patent/CL2023001775A1/en unknown
- 2023-06-16 CO CONC2023/0007904A patent/CO2023007904A2/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005019256A2 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
WO2008015239A2 (en) | 2006-08-01 | 2008-02-07 | Pieris Ag | Muteins of tear lipocalin and methods for obtaining the same |
WO2011154420A2 (en) | 2010-06-08 | 2011-12-15 | Pieris Ag | Tear lipocalin muteins binding il-4 r alpha |
WO2013087660A1 (en) | 2011-12-13 | 2013-06-20 | Pieris Ag | Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors |
WO2020201038A1 (en) * | 2019-03-29 | 2020-10-08 | Pieris Pharmaceuticals Gmbh | Inhaled administration of lipocalin muteins |
WO2020200960A1 (en) | 2019-03-29 | 2020-10-08 | Astrazeneca Ab | Lipocalin mutein for treatment of asthma |
Non-Patent Citations (23)
Title |
---|
"SWISS-PROT", Database accession no. P31025 |
"UniProt", Database accession no. P24394 |
ALTSCHUL ET AL., J MOL BIOL, 1990 |
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410 |
ALTSCHUL ET AL., NUCLEIC ACIDS RES, 1997 |
ALTSCHUL ET AL., NUCLEICACIDS RES., vol. 25, 1997, pages 3389 - 3402 |
BREUSTEDT, D.A. ET AL., J. BIOL. CHEM., vol. 280, no. 1, 2005, pages 484 - 493 |
FLOWER D: "The lipocalin protein family: structure and function", BIOCHEMICAL JOURNAL, PUBLISHED BY PORTLAND PRESS ON BEHALF OF THE BIOCHEMICAL SOCIETY, GB, vol. 318, 1 January 1996 (1996-01-01), pages 1 - 14, XP002095126, ISSN: 0264-6021 * |
FLOWER, D.R. ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1482, 2000, pages 337 - 350 |
FLOWER, D.R., BIOCHEM. J., vol. 318, 1996, pages 1 - 14 |
GASYMOV, O.K. ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1433, 1999, pages 307 - 320 |
GLASGOW, B.J. ET AL., CURR. EYE RES., vol. 14, 1995, pages 363 - 372 |
HUGOSSON S ET AL., PHARM FORUM, vol. 19, no. 3, 1993, pages 5458 - 5466 |
INGMAR BRUNS ET AL: "First-in-human data for the inhaled IL-4R? antagonist AZD1402/PRS-060 reveals a promising clinical profile for the treatment of asthma", 17 May 2019 (2019-05-17), XP055699994, Retrieved from the Internet <URL:https://d1io3yog0oux5.cloudfront.net/_b78ba3775693b210a508554b6a5082c1/pierisag/db/164/2282/pdf/PRS-060+1a+Poster_ATS+2019.pdf> [retrieved on 20200602] * |
INGMAR BRUNS ET AL: "Multiple ascending dose study of the inhaled IL-4R? antagonist, AZD1402/PRS-060, in mild asthmatics demonstrates robust FeNO reduction and a promising clinical profile for the treatment of asthma", 28 September 2019 (2019-09-28), XP055699973, Retrieved from the Internet <URL:https://d1io3yog0oux5.cloudfront.net/_b78ba3775693b210a508554b6a5082c1/pierisag/db/164/2299/pdf/191001+PRS060MADslides.pdf> [retrieved on 20200602] * |
PEARSONLIPMAN, PROC. NATL. ACAD. SCI. USA, vol. 85, no. 8, 1988, pages 2444 - 2448 |
PERVAIZ, S.BREW, K., FASEB J., vol. 1, 1987, pages 209 - 214 |
RAUNDHAL ET AL.: "Current concepts of severe asthma", J. CLIN. INVEST., vol. 126, 2016, pages 2394 - 2403 |
SCHLEHUBER, S.SKERRA, A., BIOPHYS. CHEM., vol. 96, 2002, pages 213 - 228 |
SKERRA, A., REV. MOL. BIOTECHNOL., vol. 74, 2001, pages 257 - 275 |
SMITH ET AL., J. MOL. BIOL., vol. 147, 1981, pages 195 - 197 |
SMITHWATERMAN, J MOL BIOL, 1981 |
YOU, J. ET AL., ELECTROPHORESIS, vol. 31, 2010, pages 1853 - 1861 |
Also Published As
Publication number | Publication date |
---|---|
EP4262845A1 (en) | 2023-10-25 |
CN116916945A (en) | 2023-10-20 |
CR20230265A (en) | 2023-09-29 |
CL2023001775A1 (en) | 2024-01-19 |
AU2021399151A1 (en) | 2023-07-27 |
JP2023553703A (en) | 2023-12-25 |
CA3199479A1 (en) | 2022-06-23 |
TW202241490A (en) | 2022-11-01 |
CO2023007904A2 (en) | 2023-10-30 |
IL303729A (en) | 2023-08-01 |
AR124436A1 (en) | 2023-03-29 |
KR20230121785A (en) | 2023-08-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
USRE43711E1 (en) | Pulmonary delivery for levodopa | |
Harsch | Inhaled insulins: their potential in the treatment of diabetes mellitus | |
US20020141946A1 (en) | Particles for inhalation having rapid release properties | |
EP3332767B1 (en) | Liquid inhalation formulation comprising rpl554 | |
US20030064928A1 (en) | Therapeutic preparations for inhalation | |
US7855177B1 (en) | Methods and kits for preventing hypoglycemia | |
Minne et al. | Optimization of the aerosolization properties of an inhalation dry powder based on selection of excipients | |
JP2003519175A (en) | Methods for pulmonary delivery of interleukin-2 | |
KR20100047866A (en) | Pharmaceutical polypeptide dry powder aerosol formulation and method of preparation | |
Siekmeier et al. | Treatment of systemic diseases by inhalation of biomolecule aerosols | |
CA3133422A1 (en) | Lipocalin mutein for treatment of asthma | |
US20220265549A1 (en) | Pharmaceutical composition comprising ensifentrine | |
WO2022129629A1 (en) | Lipocalin mutein dry powder formulation for treatment of asthma | |
EP3203984B1 (en) | Pharmaceutical composition containing budesonide and formoterol. | |
US20070123449A1 (en) | High load particles for inhalation having rapid release properties | |
Ranade | Inhalation therapy: new delivery systems |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21844230 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3199479 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2023/007174 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180085274.3 Country of ref document: CN Ref document number: 2023536889 Country of ref document: JP Ref document number: 001901-2023 Country of ref document: PE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023011930 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20237023191 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112023011930 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230615 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021844230 Country of ref document: EP Effective date: 20230718 |
|
ENP | Entry into the national phase |
Ref document number: 2021399151 Country of ref document: AU Date of ref document: 20211220 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 523441160 Country of ref document: SA |